Introduction {#s1}
============

During central nervous system (CNS) development, a neuron extends its axon through a complex yet precise path to reach its final destination by sensing extracellular signals called guidance cues. These cues are sensed by the growth cone, a motile structure at the extending axon edge, and they control growth cone motility through directed cytoskeletal remodeling. Netrins, slits, semaphorins, and ephrins are the major classic guidance cues and elicit attractive or repulsive responses in growth cones via specific receptors ([@bib2]; [@bib10]; [@bib17]; [@bib22]; [@bib38]; [@bib40]; [@bib42]; [@bib66]). An important aspect of axon guidance is the spatial and temporal control of response to the guidance cues. For example, the spinal cord commissural axon reaching the midline senses netrin-1, secreted from the floorplate as a chemoattractive cue; however, once it has crossed the floorplate, this cue becomes repulsive ([@bib40]; [@bib41]; [@bib72]; [@bib89]). Furthermore, the spatiotemporally restricted expression of Robo3 alternative splicing isoforms in spinal cord commissure axons are essential for the switching of the growth cone response to the axon guidance cues ([@bib9]), indicating that spatiotemporally regulated protein isoform expression and diversity is crucial to establish proper neuronal networks.

Alternative splicing and alternative polyadenylation can produce multiple messenger RNAs (mRNAs) possessing distinct coding and regulatory sequences from a single gene. The regulated processes that generate such mRNA diversity are orchestrated by RNA-binding proteins (RBPs). In the nervous system, alternative splicing has many important roles, including controlling the spatial and temporal expression of protein isoforms that are necessary for neurodevelopment and the modification of synaptic plasticity ([@bib7]; [@bib49]; [@bib77]). Significantly, human genetic studies have indicated that RNA misregulation resulting from defects in RBP expression and function are linked to numerous diseases, including Fragile X syndrome, spinal muscular atrophy, spinocerebellar ataxias, motoneuron disease and others ([@bib11]; [@bib14]; [@bib51]).

NOVA1 and NOVA2, RBPs initially identified as targets in autoimmune motor neuron disease ([@bib4]; [@bib13]), are RNA-binding splicing regulators specifically expressed in neurons in the CNS ([@bib5]; [@bib86]). NOVA1 and NOVA2 harbor three KH-type RNA binding domains, and in vitro RNA selection ([@bib6]; [@bib36]; [@bib86]) and X-ray crystallography ([@bib44]; [@bib71]) demonstrate that NOVA1 and NOVA2 bind directly to RNA sequences harboring YCAY motifs. The development of RNA:RBP crosslinking and immunoprecipitation (CLIP) ([@bib74]; [@bib75]) followed by high-throughput sequencing (HITS-CLIP) ([@bib49]) methods has enabled identification of genome-wide RBP:RNA interaction maps in vivo. The bioinformatic integration of HITS-CLIP binding data and functional outcome revealed by exon junction microarray and RNA-seq data sets led to the conclusion that NOVA regulates alternative splicing following the rule that the position of NOVA binding to pre-mRNA predicts its action to enhance or inhibit alternate exon inclusion ([@bib49]; [@bib76]; [@bib77]; [@bib83], [@bib88]). These analyses revealed \~700 NOVA1/NOVA2 target alternate exons and allowed to predict the biological process regulated by NOVA1/NOVA2. However, these studies have found no biochemical actions that were unique to NOVA1 versus NOVA2 paralogues, reflecting their nearly identical KH-type RNA binding domains.

In the present work, we find that NOVA2 uniquely regulates a series of alternative splicing events of axon guidance related genes, including deleted in colorectal carcinoma (*Dcc*), Roundabout, Axon Guidance Receptor, Homolog 2 (*Robo2*), Slit homolog 2 (*Slit2*), and EPH Receptor A5 (*Epha5*). These findings derived from combining transcriptome-wide NOVA1 and NOVA2 specific HITS-CLIP with RNA-seq analysis in the cortex of mice lacking either *Nova1* or *Nova2. Nova2* deficiency results in some common phenotypes, such as severe growth retardation, as previously reported in *Nova1-/-* mice ([@bib35]), as well as unique phenotypes, including agenesis of the corpus callosum (ACC) in *Nova2-/-* mice. Unexpectedly, given that motoneurons express both NOVA1 and NOVA2, a subset of motoneuron axons directed to the ventral diaphragm show outgrowth defects in *Nova2-/-* but not *Nova1-/-* mice. In addition, the efferent innervation to the cochlea which is derived during development from a ventral subpopulation of facial motoneurons, is normal in *Nova1-/-* mice, reduced in *Nova2-/-* mice, and completely stalled in the absence of both *Nova1* and *Nova2*, suggesting that alternative splicing regulator NOVA2 plays critical roles in axon pathfinding context in mammals and that NOVA1 may have a cooperative role in this process. Based on these observations from genome-wide and histological analyses of *Nova2-/-* mice, we conclude that NOVA2-mediated RNA regulation is essential for CNS development by regulating neural networks wiring.

Results {#s2}
=======

Generation of *Nova2* null mice and growth retardation in *Nova2* null mice {#s2-1}
---------------------------------------------------------------------------

We utilized targeted mutagenesis to disrupt *Nova2* genetic function in mice. A targeting cassette was designed to replace the first exon of *Nova2* gene ([Figure 1A](#fig1){ref-type="fig"}). The genotype of the resulting progenies was confirmed both by Southern blot ([Figure 1B](#fig1){ref-type="fig"}) and PCR ([Figure 1C](#fig1){ref-type="fig"}). The progeny displayed the expected Mendelian ratio of mice for the heterozygous and homozygous *Nova2* mutation. To confirm that homozygous *Nova2* mutant mice did not express NOVA2 protein, Western blot analysis was carried out on protein extracts from P0 cortex ([Figure 1D](#fig1){ref-type="fig"}) of wild-type, *Nova2-/-,* and *Nova1-/-* mice, using anti-NOVA1, anti-NOVA2, and antisera from a patient with paraneoplastic opsoclonus-myoclonus ataxia (POMA), which recognizes all NOVA protein species ([@bib86]). Expression of NOVA2 protein isoforms was absent in *Nova2-/-*mice ([Figure 1D](#fig1){ref-type="fig"}).10.7554/eLife.14371.003Figure 1.Generation of *Nova2* null mice and characterization of SuperNOVA2.(**Ai**) The wild-type *Nova2* locus illustrated contains the first exon (green box, with initiator ATG indicated). (**Aii**) A targeting construct was generated harboring a genomic fragment (left: 2.2 kb) flanking the initiator methionine, an *IRES-Cre FRT-NEO-FRT (FNF*) insertion, and an intronic genomic fragment flanking the first coding exon (right: 6 kb). (**Aiii**) The *Nova2* null locus following FLP-mediated excision of *FNF* cassette. Restriction enzyme sites were indicated for BamHI (**B**), HindIII (**H**), SacI (**S**), SmaI (Sm) and XbaI (X). The probes position used for Southern blot was indicated in *red*. (**B**) Genotypic analysis of *Nova2* null mice. Southern blot analysis was performed on tail DNA digested with BamHI, using the probe described in (**A**). (**C**) Genotyping PCR analysis of *Nova2* null mice. (**D**) Western blot analysis of NOVA1 and NOVA2 proteins. Extracts of mouse cortex (10 μg/lane) were made from age-matched P0 wild-type, *Nova2-/-*, and *Nova1-/-* mice, loaded on SDS-PAGE gels, and blotted with anti-pan NOVA (POMA antisera), anti-NOVA1 specific, anti-NOVA2 specific, anti-PTBP2, and anti-GAPDH antibodies. Quantification and comparison of NOVA1 and NOVA2 proteins expression amounts in the cortex of wild-type, *Nova2-/-*, and *Nova1-/-* mice. Data are presented as mean ± SD. \*p\<0.05, \*\*p\<0.01 (n = 3, Tukey's multiple comparison test). (**E**) Characterization of superNOVA2. *Left Diagram* showing a putative superNOVA2 initiator methionine (*green*) positioned 192 nt upstream of the known *Nova2* initiator methionine. *Right panel* showing the NOVA proteins mobility on electrophoresis.**DOI:** [http://dx.doi.org/10.7554/eLife.14371.003](10.7554/eLife.14371.003)10.7554/eLife.14371.004Figure 1---figure supplement 1.Growth retardation of *Nova2*-/- mice.(**A**) Growth curves of *Nova2-/-, Nova2*+/-, and *Nova2*+/+ littermates. Weights of *Nova2-/- (blue), Nova2*+/- (*green*), and *Nova2*+/+ (*red*) mice were studied from birth to age 14 days (n \> = 7). Data are presented as mean ± SD. (**B**) Survival curves of *Nova2-/- (blue), Nova2*+/- (*green*), and *Nova2*+/+ (*red*) littermates. *Nova2*-/- mice died on average between P14-P18, whereas *Nova2*+/- showed no difference in survival from *Nova*2+/+ mice. Data are presented as mean ± SD.**DOI:** [http://dx.doi.org/10.7554/eLife.14371.004](10.7554/eLife.14371.004)10.7554/eLife.14371.005Figure 1---figure supplement 2.Anti-NOVA2 and anti-NOVA1 antibodies specificity.Coronal brain sections of E16.5 wild-type, *Nova1*-/-, and *Nova2*-/-, stained for NOVA1 (***green***), NOVA2 (***red***), and DAPI (***blue***). Scale bar; 500 μm. (**B**) Specificity of antibodies for immunoprecipitation.**DOI:** [http://dx.doi.org/10.7554/eLife.14371.005](10.7554/eLife.14371.005)

Interestingly, more than one protein isoform was absent in protein extracts from *Nova2* null mice: a single 50--52 kDa NOVA2 protein species corresponding to the predicted size of the previously described *Nova2* ORF, and a series of previously described ([@bib75]; [@bib21]) but uncharacterized protein isoforms of \~70 kDa recognized by anti-NOVA2 antibody and POMA antisera, which we named SuperNOVA2. We found three putative initiator ATG sequences upstream of the known *Nova2* start codon on the 5' UTR of the transcript. The mobility of SuperNOVA2 on electrophoresis was comparable with the protein product expressed from SuperNOVA2 plasmid containing full-length sequence of the 5' UTR ([Figure 1E](#fig1){ref-type="fig"}), confirming that SuperNOVA2 translation started from an upstream codon in the *Nova2* 5' UTR. Using anti-NOVA1 or SuperNOVA2/NOVA2 specific antibodies, we found that NOVA1 protein levels were significantly increased, by \~40% in *Nova2-/-* mice cortex ([Figure 1D](#fig1){ref-type="fig"}) but NOVA1 anatomic expression pattern was similar to wild-type mice sections (data not shown). Thus NOVA1 has partially overlapping distributions with SuperNOVA2/NOVA2 (hereinafter we defined SuperNOVA2/NOVA2 as NOVA2), is upregulated by unknown means in the absence of *Nova2*, and may have partially redundant functions with NOVA2 in the cortex.

*Nova2* null animals were born indistinguishable from littermates but failed to thrive, demonstrating progressive motor dysfunction and overt motor weakness, and they died an average of 14--18 days after birth ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). There was no apparent phenotype in *Nova2* heterozygotes, although we previously found that when assessed by electroencephalography, 6 month old *Nova2+/-* (and *Nova1+/-*) mice had frequent synchronous cortical interictal discharges consistent with epilepsy ([@bib21]). In conclusion, we demonstrate that the *Nova2* gene encodes for multiple protein isoforms, including an identified \~70 kDa SuperNOVA2 isoform, and that *Nova2* is necessary for post-natal survival.

Genome-wide NOVA1- and NOVA2-RNA interaction maps {#s2-2}
-------------------------------------------------

The NOVA1/2 splicing-regulatory network and its target alternative splicing events have been previously defined by utilizing NOVA2 and pan-NOVA HITS-CLIP data, splicing sensitive microarray data, NOVA1/2-binding motifs, and integrative modeling ([@bib49]; [@bib76]; [@bib77]; [@bib88]), yet these data sets were integrated data sets from multiple developmental stages, CNS regions, and *Nova1/Nova2* genotypes. Relatively little is known about the biologic consequences of NOVA1 and NOVA2 action and about the functional differences between NOVA1 and NOVA2 in a specified CNS region and at a particular developmental stage.

To identify NOVA1 and NOVA2 direct RNA targets in E18.5 cortex, a transcriptome-wide library of NOVA1-RNA and NOVA2-RNA interactions were generated by HITS-CLIP from E18.5 wild-type mice cortex and sequenced. NOVA1 and NOVA2 CLIP reads were filtered and aligned to the mouse genome (mm9). A total of 2,318,553 unique NOVA2 CLIP tags were obtained from three biological replicates (483,446, 836,678, and 998,429 unique tags, respectively), with a total of 139,007 clusters from at least two or three biologic replicates (defined as biological complexity of two (BC2)). A total of 910,342 unique NOVA1 CLIP tags were obtained from three biological replicates (319,904, 292,709, and 297,729 unique tags, respectively), with a total of 54,546 clusters (BC2). To identify sequence features most commonly associated with either NOVA1-RNA or NOVA2-RNA interactions, 4 nucleotide (nt) long motifs were counted in BC2 NOVA1 and NOVA2 clusters and in a set of shuffled control sequences as a control. Each of the top five ranking tetramers in NOVA1 and NOVA2 clusters were the same (UCAU, CAUC, CAUU, UCAC, and UUCA) ([Figure 2A](#fig2){ref-type="fig"}) and coincided with the previously identified YCAY NOVA binding motif. Enrichment of the YCAY motif around NOVA1 and NOVA2 clusters was comparable between NOVA1 and NOVA2 and greatly enriched within NOVA1 and NOVA2 CLIP clusters ([Figure 2B](#fig2){ref-type="fig"}), suggesting that NOVA1 and NOVA2 recognized the same YCAY RNA sequence. NOVA1 and NOVA2 CLIP tag positions on known NOVA regulated alternatively spliced exons ([@bib88]) were comparable ([Figure 2C and D](#fig2){ref-type="fig"}). For example, alternative splicing of *Agrn* minigene containing exon 31--34 were regulated by NOVA1 and NOVA2 in the same splicing direction, in this case mediating the inclusion of the exon ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), indicating that NOVA1 and NOVA2 have similar RNA interaction profiles on NOVA1/2 target alternative splicing sites and are capable of regulating the same alternative splicing events.10.7554/eLife.14371.006Figure 2.NOVA2 and NOVA1 HITS-CLIP.(**A**) Top 5 tetramers present in BC2 NOVA2 and NOVA1 sequences compared with the shuffled control sequences. The sequences corresponding to YCAY motif were high-lighted with *magenta*. (**B**) Enrichment of YCAY motif near NOVA2 (*blue*) and NOVA1 (*red*) clusters. (**C**) Distribution of BC2 NOVA2 (*blue*) and NOVA1 (*red*) CLIP tags (*Y*-axis: CLIP tags density in each 25 nt window) near known NOVA1/2 targeted alternative exons silencing (*top panel*) and splicing (*bottom panel*) events. (**D**) Examples of NOVA2 and NOVA1 CLIP cluster location near known NOVA1/2-target alternative splicing exon (*top panel*; silencing event, *Neo1* exon 25--27, *bottom panel*; splicing event, *Epha5* exon 6--8). (**E**) Summary of robust NOVA2 (*blue*) and NOVA1 (*red*) CLIP BC2 clusters consisted of a minimum of 10 tags. (**F**) Genomic distribution of BC2 NOVA2 (*left*) and NOVA1 (*right*) clusters consisted of a minimum of 10 tags.**DOI:** [http://dx.doi.org/10.7554/eLife.14371.006](10.7554/eLife.14371.006)10.7554/eLife.14371.007Figure 2---figure supplement 1.Alternative splicing regulation of *Agrn* minigene by NOVA proteins.Alternative splicing impact on *Agrn* minigene was examined in HEK293T cells with or without NOVA proteins conditions.**DOI:** [http://dx.doi.org/10.7554/eLife.14371.007](10.7554/eLife.14371.007)10.7554/eLife.14371.008Figure 2---figure supplement 2.Genomic distribution of BC2 NOVA2 specific (*left*), NOVA1 specific (*middle*), and NOVA2/NOVA1 common clusters consisted of a minimum of 10 tags.**DOI:** [http://dx.doi.org/10.7554/eLife.14371.008](10.7554/eLife.14371.008)10.7554/eLife.14371.009Figure 2---figure supplement 3.NOVA1 and NOVA2 expression in the mouse embryonic brain.(**A**) Immunohistochemistry of NOVA1 (***b**, **f**, **j**, **n**: green*) and NOVA2 (***c**, **g**, **k**, **o**: red*) in E18.5 coronal sections (***a**--**d***), sagittal sections (***e**--**h***), neocortex (***i**--**p***). Scale bars; 500 μm (***a**--**h***), 50 μm (***i**--**l***).**DOI:** [http://dx.doi.org/10.7554/eLife.14371.009](10.7554/eLife.14371.009)

Twenty-six percent or eighteen percent, respectively, of the NOVA2 or NOVA1 BC2 clusters consisted of a minimum of 10 tags (defined as peak height (PH); NOVA2; 36,591 of 139,007, NOVA1; 9988 of 54,546). 80.1% of NOVA1 clusters were shared with NOVA2 cluster positions, while 22.1% of NOVA2 clusters overlapped with NOVA1 ([Figure 2E](#fig2){ref-type="fig"}). Interestingly, the genomic distribution of NOVA2 clusters and NOVA1 showed different distributions within their target transcripts ([Figure 2F](#fig2){ref-type="fig"} and [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). 77.7% of NOVA2 clusters were located in introns and 13.9% in exons (5' UTR, CDS, and 3' UTR) compared to 45.4% of NOVA1 clusters that were in introns and 45.1% in exons ([Figure 2F](#fig2){ref-type="fig"}). 84.9% of NOVA2 specific BC2 clusters (PH\>=10) were enriched in introns, while 74.1% of NOVA1 specific BC2 clusters (PH\>=10) were in exons ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}), indicating that NOVA2 binds preferentially to introns than exons, suggesting that NOVA2 may play a greater nuclear role than NOVA1, and demonstrating that RNA-interaction profiles on a genome-wide scale are different between NOVA homologues.

The distribution of NOVA2 throughout the brain mirrored previous immunohistochemical and in situ hybridization data ([@bib86]) showed that NOVA2 was expressed at high levels in cortex and hippocampus, and at lower levels in midbrain and spinal cord, where NOVA1 was expressed at high levels in a generally reciprocal fashion, with low levels in the cortex and relatively high levels in the midbrain and spinal cord ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}). The NOVA2 expressed cell in the cortical plate of neocortex was ubiquitously distributed at comparable expression level, yet NOVA1 was expressed in the specified cell types. Taken together, the HITS-CLIP and immunohistochemical data suggest that NOVA1 and NOVA2 perform unique biological functions in different brain areas and cell types, and that in those few cortical neurons expressing NOVA1, NOVA2 might be expected to have some redundant activity, while the reciprocal may not so often be the case.

NOVA2-dependent alternative splicing changes of axon guidance related genes {#s2-3}
---------------------------------------------------------------------------

To identify NOVA1 or NOVA2 target transcripts whose abundance or alternative splicing was changed in either *Nova1-/-* or *Nova2-/-* cortex, paired-end 125 nucleotide RNA-seq libraries were prepared from littermate E18.5 wild-type, *Nova1-/-*, *and Nova2-/-* mice cortex. A total of 225,054,059 and 213,596,515 unique reads were obtained from three biological replicates of wild-type and *Nova1-/-* mice, respectively, and a total of 190,282,241 and 180,200,564 unique reads were obtained from three biological replicates of wild-type and *Nova2-/-* mice, respectively. These experiments showed that the abundance of 60 transcripts were significantly changed in *Nova2-/-* mice compared to only 2 transcripts which showed steady-state changes in *Nova1-/-* mice compared to wild-type littermates (FDR\<0.05 and \|log~2~FC\|\>=1) ([Figure 3A](#fig3){ref-type="fig"}), consistent with lower levels of NOVA1 expression in cortex. More changes were seen in analyzing splicing-dependent changes, and this pattern of differential NOVA2 and NOVA1 effects was also seen. We integrated NOVA1 and NOVA2 specific HITS-CLIP data, RNA-seq data, and NOVA binding YCAY motifs to define 1991 NOVA2 and 58 NOVA1-mediated alternative splicing events in the mouse cortex ([Figure 3B](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Interestingly, there was no correlation between *delta* I (*Δ*I) of wild-type versus *Nova1-/-* and wild-type versus *Nova2-/-* (R = 0.09) ([Figure 3C](#fig3){ref-type="fig"}). Taken together, this data shows that *Nova1* and *Nova2* have different RNA regulatory networks in developing cortical neurons; while the quantitative differences likely relate to the greater and more unique cellular expression of NOVA2 relative to NOVA1 in cortex, they also support the suggestion that the two NOVA homologues may regulate unique biological processes.10.7554/eLife.14371.010Figure 3.RNA-seq analysis in either *Nova2-/-* or *Nova1-/-* versus littermate wild-type control.(**A**) RNA abundance changes in *Nova2-/-* and *Nova1-/-* mice cortex and comparison of its correlation in *Nova2-/-* with in *Nova1-/- mice. X*-axis and *Y*-axis indicated log~2~(*Nova2-KO*/wild-type fold change (FC)) and log~2~(*Nova1-KO*/wild-type FC), respectively. Transcripts significantly changed in *Nova2-/-* and *Nova1-/-* mice cortex were shown in *blue* and *red*, respectively (FDR\<0.05 and log~2~\|FC\|\>=1). (**B**) Summary of NOVA2- and NOVA1-dependent alternative splicing changes that showed \|*Δ*I\| \>= 0.1 (FDR \< 0.1) ([@bib76]) and that contained YCAY motif(s) within BC2 NOVA1 or NOVA2 HITS-CLIP clusters on alternative splicing exons and/or its upstream/downstream introns. 1991 NOVA2-target alternative splicing events on 540 genes (known \[[@bib88]\]; 780 events, novel; 1211 events), 58 NOVA1-target events on 20 genes (known; 0 events, novel 58 events). (**C**) Correlation of *Nova2-* and *Nova1*-deficient impact on alternative splicing events. *X*-axis and *Y*-axis indicated *Δ*I of wild-type (WT) vs *Nova2-/-* and vs *Nova1-/-*, respectively.**DOI:** [http://dx.doi.org/10.7554/eLife.14371.010](10.7554/eLife.14371.010)10.7554/eLife.14371.011Figure 3---source data 1.Gene Ontology (GO) terms associated with NOVA2-target alternative splicing exons.Summary of GO analysis of NOVA2-regulated genes performed using DAVID Bioinformatics Resources (<https://david.ncifcrf.gov>) (FDR\<0.05).**DOI:** [http://dx.doi.org/10.7554/eLife.14371.011](10.7554/eLife.14371.011)10.7554/eLife.14371.012Figure 3---source data 2.The transcriptome abundance of the neuronal differentiation markers in the E18.5 cortex of *Nova1-/-* and *Nova2-/-* mice.log2FC: log~2~ (*Nova*1 or *Nova2* mutants/wild-type) fold change.**DOI:** [http://dx.doi.org/10.7554/eLife.14371.012](10.7554/eLife.14371.012)10.7554/eLife.14371.013Figure 3---figure supplement 1.Summary of the number of alternative splicing events detected by RNA-seq analysis with/without NOVA2 or NOVA1 CLIP clusters and/or YCAY clusters.**DOI:** [http://dx.doi.org/10.7554/eLife.14371.013](10.7554/eLife.14371.013)10.7554/eLife.14371.014Figure 3---figure supplement 2.KEGG pathways over-represented among NOVA2-target genes.Axon guidance pathway (FDR\<0.05). *Red stars* indicating NOVA2-target alternative splicing genes identified by combining RNA-seq with NOVA2 HITS-CLIP analysis. Figures obtained from GO analysis using DAVID Bioinformatics Resources (<https://david.ncifcrf.gov>).**DOI:** [http://dx.doi.org/10.7554/eLife.14371.014](10.7554/eLife.14371.014)10.7554/eLife.14371.015Figure 3---figure supplement 3.KEGG pathways over-represented among NOVA2-target genes.Adherens junction pathway (FDR\<0.05). *Red stars* indicating NOVA2-target alternative splicing genes identified by combining RNA-seq with NOVA2 HITS-CLIP analysis. Figures obtained from GO analysis using DAVID Bioinformatics Resources (<https://david.ncifcrf.gov>).**DOI:** [http://dx.doi.org/10.7554/eLife.14371.015](10.7554/eLife.14371.015)10.7554/eLife.14371.016Figure 3---figure supplement 4.RNA-seq analysis in the midbrain and hindbrain of *Nova1-/-* versus littermate wild-type control.(**A**) Summary of NOVA2-dependent (cortex) and NOVA1-dependent (midbrain and hindbrain) alternative splicing changes that showed \|*Δ*I\|\>=0.1 (FDR\<0.1). (**B**) Correlation of *Nova2*-deficient (*cortex)* and *Nova1*-deficient (midbrain and hindbrain) impact on alternative splicing events. *X*-axis and *Y*-axis indicated *ΔI* of wild-type vs *Nova2-/-* (cortex) and vs *Nova1-/-* (midbrain and hindbrain), respectively. (**C**) Examples of alternative splicing changes of the NOVA2-regulated axon guidance genes in the cortex of *Nova2-/-* and *Nova1-/-* and in the midbrain and hindbrain of *Nova1-/-* mice. Low expression genes in midbrain and hindbrain samples were filtered out. *Y*-axis indicated *ΔI. Blue; Nova2-/-* (cortex), *red; Nova1-/-* (cortex), *orange; Nova1-/-* (midbrain and hindbrain). \*p\<0.05.**DOI:** [http://dx.doi.org/10.7554/eLife.14371.016](10.7554/eLife.14371.016)

We explored the biologic pathways regulated by NOVA1 and NOVA2 with gene ontology (GO) analysis on the transcripts harboring NOVA-regulated alternative exons. Among the KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway terms associated with NOVA2-regulated genes (FDR\<0.05) were axon guidance signaling (FDR=0.0039) and adherens junctions signaling (FDR = 0.017) ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"} and [3](#fig3s3){ref-type="fig"}). In the GO terms associated with NOVA2-regulated genes (FDR\<0.05), axonal projection related terms (cell morphogenesis, neuron projection morphogenesis, axonogenesis, cell morphogenesis involved in neuron differentiation, and cell projection morphogenesis) were also enriched ([Figure 3---source data 1](#SD1-data){ref-type="supplementary-material"}). NOVA2-dependent alternative splicing events of axon guidance related genes were validated by semi-quantitative RT-PCR with RNA prepared from E18.5 wild-type *Nova2-/-*, and *Nova1-/-* cortex ([Figure 4](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). The alternative splicing events (*Dcc* exon 17, *Slit2* exon 28b, *Robo2* exons 6b and 21, *Epha5* exon 7, *Arhgef12* exon 4, *Ppp3cb* exon 10b, *Neo1* exon 26, and *Rock1* exon 27b) were significantly changed in *Nova2-/-* but not in *Nova1-/-* mice cortex, coinciding with RNA-seq results. No association was detected in the NOVA1-regulated alternative exons GO or KEGG pathways terms, likely due to the smaller number of NOVA1-regulated transcripts in cortex.10.7554/eLife.14371.017Figure 4.NOVA2 unique alternative splicing events of axon guidance related genes in E18.5 mice cortex.*Left Diagrams* showing RefSeq annotation genes, changed alternative splicing events, RNA-seq results of wild-type (*grey*) and *Nova2-/- (blue*), NOVA2 CLIP clusters (*light blue*), RNA-seq results of wild-type (*grey*) and *Nova1-/- (red*), and NOVA1 CLIP clusters (*pink). Right panels* and *graphs* showing RT-PCR results and quantification data in E18.5 wild-type, *Nova2-/-*, and *Nova1-/-* mice cortex, respectively. \*p\<0.05, \*\*p\<0.01 (n = 3, Tukey's multiple comparison test). Data are presented as mean ± SD.**DOI:** [http://dx.doi.org/10.7554/eLife.14371.017](10.7554/eLife.14371.017)10.7554/eLife.14371.018Figure 4---figure supplement 1.NOVA2 unique alternative splicing events of axon guidance related genes in E18.5 mice cortex.*Left Diagrams* showing RefSeq annotation genes, changed alternative splicing events, RNA-seq results of wild-type (*grey*) and *Nova2-/- (blue*), NOVA2 CLIP clusters (*light blue*), RNA-seq results of wild-type (*grey*) and *Nova1-/- (red*), and NOVA1 CLIP clusters (*pink). Right panels* and *graphs* showing RT-PCR results and quantification data of *Ahrgef12, Ppp3cb, Neo1*, and *Rock1* in E18.5 wild-type, *Nova2-/-*, and *Nova1-/-* mice cortex, respectively. \*\*p\<0.01 (n=3, Tukey's multiple comparison test). Data are presented as mean ± SD.**DOI:** [http://dx.doi.org/10.7554/eLife.14371.018](10.7554/eLife.14371.018)

RNA-seq analysis in the E18.5 midbrain and hindbrain of wild-type and *Nova1-/-* mice, where NOVA1 is more abundantly expressed, identified that 119 of 1991 NOVA2-dependent alternative splicing events were changed in *Nova1*-/- mice (\|*Δ*I\|\>=0.1, FDR\<0.1) ([Figure 3---figure supplement 4A](#fig3s4){ref-type="fig"}). There was no correlation between *Δ*I of wild-type versus *Nova1-/-* (mid- and hindbrain) and wild-type versus *Nova2-/-* (cortex) (R=0.20) ([Figure 3---figure supplement 4B](#fig3s4){ref-type="fig"}) as well as identified between *Δ*I of wild-type versus *Nova1-/-* (cortex) and wild-type versus *Nova2-/-* (cortex). In the midbrain and hindbrain of *Nova1-/-* mice, only one alternative splicing event (*Robo2* exon 6b) was significantly changed in the NOVA2-regulated genes list of KEGG axon guidance pathway but it was smaller change when compared with *Δ*I of wild-type versus *Nova2-/-* (cortex) ([Figure 3---figure supplement 4C](#fig3s4){ref-type="fig"}). Taken together, these data suggest that NOVA2 regulates a distinct set of transcripts related, in particular, to axon guidance, in the E18.5 mouse cortex.

NOVA2-mediated alternative splicing switch of axon guidance genes during mouse cortical development {#s2-4}
---------------------------------------------------------------------------------------------------

To pursue the potential connection between NOVA2 and axonal guidance, we examined NOVA2 expression during cortical mouse brain development. We found that NOVA2 expression level detected by immunofluorescence was high in the cortical plate (CP) and subplate (SP) that consists of post-mitotic neurons at E18.5 ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}). Similarly a high-expression of NOVA2 in CP and SP was also observed at E12.5, E14.5, and E16.5 ([Figure 5A](#fig5){ref-type="fig"}), indicating that cortical NOVA2 expression level was progressively up-regulated during neural differentiation from neural progenitor cells (NPC).10.7554/eLife.14371.019Figure 5.NOVA2 switches developmentally regulated exons usage of axon guidance related genes.(**A**) NOVA2 expression in developing neocortex (*left panels*). High NOVA2 expression regions were high-lighted with *red* in *middle panels*. MZ: marginal zone, CP: cortical plate, SP: subplate, IZ: intermediate zone, SVZ: subventricular zone, VZ: ventricular zone. (**B**) Analysis of NOVA2-regulated exons in *Dcc, Robo2, Epha5, Slit2*, and *Neo1* in E12.5 wild-type, E18.5 wild-type, and E18.5 *Nova2-/-* cortex (*left panels*). Quantification data of RT-PCR products were shown in *right graphs*. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001 (n = 3, Tukey's multiple comparison test).**DOI:** [http://dx.doi.org/10.7554/eLife.14371.019](10.7554/eLife.14371.019)

To assess whether NOVA2 regulated alternative splicing is also regulated in a developmentally regulated manner, we compared expression of alternatively spliced NOVA2 target exons in E12.5 wild-type, E18.5 wild-type, and E18.5 *Nova2-/-* cortex ([Figure 5B](#fig5){ref-type="fig"}). This revealed that NOVA2-target splicing events were developmentally regulated between E12.5 and E18.5, such that splicing in E18.5 *Nova2-/-* cortex reverted to patterns seen earlier in E12.5 wild-type cortex. Based on these observations, we conclude that NOVA2 switches the alternative splicing patterns of a series of axon guidance genes during mouse cortical development.

Axon guidance defects in the brain of *Nova2* but not *Nova1* null mice {#s2-5}
-----------------------------------------------------------------------

The observations that NOVA2 regulates alternative splicing events in transcripts encoding axon guidance signaling factors led us to test whether axon guidance itself is affected in *Nova2* null mice. When coronal and horizontal sections of E18.5 mice brains were double-immunostained for L1, an axonal marker, and TAG-1, a corticofugal axon marker, we discovered that *Nova2-/-* mice, but not wild-type littermates, had agenesis of the corpus callosum (ACC) (14/14 mice) ([Figure 6](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). ACC was in all *Nova2-/-* mice serial sections examined ([Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}), was seen along with Probst bundles (abnormal collections of cells characteristically seen in patients with ACC; *arrows* in [Figure 6A--o](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1A--l](#fig6s1){ref-type="fig"}), and was also clearly evident in sections stained with the pioneer axon marker Neuropilin-1 ([Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}). Interestingly, *Nova1-/-* mice showed normal CC formation ([Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}). The anterior commissure axons were observed in both *Nova2-/-* and *Nova1-/-* mice ([Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}).10.7554/eLife.14371.020Figure 6.Agenesis of corpus callosum in Nova2-/- mice.(**A**) Immunohistochemistry of L1 (*green*; a,e,i,m), TAG1 (*red*; b,f,j,n) proteins, DAPI (*blue*; c,g,k, o) and merged views (d,h,l,p) on coronal sections in E18.5 wild-type (a--d, i--l) and *Nova2-/-* (e-h, m--p) littermates. (i--p) Higher magnified view of anterior commissure region of a--h. Arrows indicated Probst bundles. Scale bars; 500 μm. (**B**) Commissure axons pathfinding defect in *Nova2-/-* mice. Coronal sections of the anterior (a,b) and posterior (c,d) telencephalon in P0 wild-type (a,c) and *Nova2-/-* (b,d) mice showing anterogradely labeled fibers after DiI crystal placements in the cingulate cortex. Arrows indicated the cortico-thalamic axon terminal into dorsal thalamus. Asterisks: DiI placed positions. Scale bars; 500 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.14371.020](10.7554/eLife.14371.020)10.7554/eLife.14371.021Figure 6---figure supplement 1.Loss of corpus callosum in *Nova2-/-* but not *Nova1-/-* mice.(**A**) Immunohistochemistry of L1 (a,d,g,j), TAG1 (b,e,h,k) proteins, and DAPI (c,f,I,l) on horizontal sections in E18.5 wild-type (a--c, g--i) and *Nova2-/-* (d--f, j--l) littermates. (g--l) Higher magnified view of anterior commissure region of (a---f). Arrows indicated Probst bundles. Scale bars; 500 μm. (**B**) Serial section images of L1 immunostaining from anterior brain position to posterior. Wild-type images shows on ***left panels*** and *Nova2*-/- images on ***right panels***. Scale bar; 500 μm. (**C**) Coronal brain sections of E18.5 wild-type (a--d) and *Nova2*-/- (e--h) littermates, stained for L1 (*green*; aand e), Neuropilin-1 (a pioneer axon marker; ***red***; b and f), DAPI (***blue***;cand g), and merged views (d and h). Scale bar; 500 um. (**D**) Normal formation of corpus callosum in *Nova1*-/- mice. Coronal brain sections of E18.5 wild-type and *Nova1*-/- littermates, stained for L1 (*upper panels*), NOVA1 (*middle panels*), and DAPI (*lower panels*). Scale bar; 500 um. (**E**) Commissure axons pathfinding defect in *Nova2-/-* mice. Coronal sections in wild-type (a) and *Nova2-/-* (b) mice showing anterogradely labeled fibers after DiI crystal placements in lateral neocortex. Asterisks: DiI placed positions. Scale bars; 500 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.14371.021](10.7554/eLife.14371.021)10.7554/eLife.14371.022Figure 6---figure supplement 2.Normal formation of anterior commissure axons in *Nova1-/-* and *Nova2-/-* mice.Coronal brain sections of E18.5 wild-type, *Nova1-/-* and *Nova2-/-*, stained for DAPI. Scale bar; 500 um. *Red arrows:* anterior commissure axons.**DOI:** [http://dx.doi.org/10.7554/eLife.14371.022](10.7554/eLife.14371.022)10.7554/eLife.14371.023Figure 6---figure supplement 3.Alternative splicing changes of the genes associated with mouse ACC phenotypes and human ACC syndromes.*Left Diagrams* showing RefSeq annotation genes, changed alternative splicing events, RNA-seq results of wild-type (*grey*) and *Nova2-/- (blue*), NOVA2 CLIP clusters (*light blue*), RNA-seq results of wild-type (*grey*) and *Nova1-/- (red*), and NOVA1 CLIP clusters (*pink). Right panels* and *graphs* showing RT-PCR results and quantification data in E18.5 wild-type, *Nova2-/-*, and *Nova1-/-* mice cortex, respectively. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001 (n = 3, Tukey's multiple comparison test). Data are presented as mean ± SD.**DOI:** [http://dx.doi.org/10.7554/eLife.14371.023](10.7554/eLife.14371.023)

To independently corroborate these observations, corpus callosal commissural axons were visualized with DiI anterograde tracer placed into the cingulate cortex. No CC commissural axons were detected that crossed the midline in *Nova2-/-* brain, however, were clearly detected in anterior and posterior sections of wild-type brain at P0 ([Figure 6B](#fig6){ref-type="fig"}). Corpus callosal commissural axons from the lateral neocortex also failed to cross the midline in *Nova2-/-* mice ([Figure 6---figure supplement 1E](#fig6s1){ref-type="fig"}). Interestingly, corticothalamic axons of both wild-type and *Nova2-/-* mice terminated in a similar thalamic region at E18.5 (*arrows* in [Figure 6B](#fig6){ref-type="fig"}), indicating that only specific aspects of axon guidance are disrupted in *Nova2* null mice. These observations suggest that *Nova2* but not *Nova1* regulate a series of alternative splicing events that are necessary for forming the CC, and demonstrate that NOVA2 and NOVA1 have different functions in CC axon guidance pathways.

To understand the axon guidance phenotype in more detail, we compared the pathway of L1 positive axons traversing the upper cortical layer in the cortex of *Nova2-/-* and wild-type mice at E16.5 and E18.5 (E16.5; [Figure 7](#fig7){ref-type="fig"} and E18.5; [Figure 6A](#fig6){ref-type="fig"}). In wild-type mice, L1 positive axons passing between the subplate and subventricular zone were detected as one wide bundle, whereas in *Nova2-/-* mice L1 positive axon routes were separated into two bundles ([Figure 7A](#fig7){ref-type="fig"}). The L1 positive axons detected in the deeper cortical layer in *Nova2-/-* appeared normal, in that they passed through similar cortical layers as did axons in wild-type mice. In contrast, separated axons passing through the upper L1 positive axonal pathway, which were Netrin-G1 (NTNG1) positive axons, were only seen in *Nova2-/-* mice and were passed along a subplate path enriched in NURR1 (a subplate marker), as revealed by L1/NTNG1 or L1/NURR1 double-immunostaining ([Figure 7B](#fig7){ref-type="fig"} and [Figure 7C](#fig7){ref-type="fig"}). These results indicate that only a portion of the L1 positive axonal path, which is NTNG1 positive, is specifically affected by the absence of *Nova2*. We conclude that NOVA2 plays a role as a modifier for a unique set of neuron-specific axons in the developing cortex.10.7554/eLife.14371.024Figure 7.Abnormal thalamo-cortical path in the cortex of *Nova2-/-* mice.(**A**) Immunohistochemistry of L1 (c,d) and NOVA2 (e,f) on coronal sections in wild-type (a,c,e,g) and *Nova2-/-* (b,d,f,h) at E16.5. (a,b) Merged coronal section views of L1 (*green*), NOVA2 (*red*), and DAPI (*blue*). (c-h) Higher magnified view of neocortex of (**Aa**) and (**Ab**). Scale bars; 200 μm (a,b), 50 μm (c--h). (**B**) Immunohistochemistry of L1 (c,d) and NTNG1 (e,f) on coronal sections in wild-type (a, c,e,g) and *Nova2-/-* (b,d,f,h) at E16.5. (a,b) Merged coronal section views of L1 (*green*), NTNG1 (*red*), and DAPI (*blue*). (c-h) Higher magnified view of neocortex of (**Ba**) and (**Bb**). Scale bars; 500 μm (a,b), 50 μm (c--h). (**C**) Immunohistochemistry of L1 (c,d) and NURR1 (e,f) in the cortex of wild-type (a,c,e,g) and *Nova2-/-* (b,d,f,h) at E16.5. (a,b) Merged views of L1 (*green*), NURR1 (*red*), and DAPI (*blue*). Scale bar; 50 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.14371.024](10.7554/eLife.14371.024)10.7554/eLife.14371.025Figure 8.Innervation defect in ventral diaphragm of *Nova2-/-* mice.Whole mount staining images of axons (*green*) and muscle (*white* in **A***, blue* in **B**) in diaphragm of E18.5 (**A**), E14.5 and E16.5 (**B**) wild-type and *Nova1/2* mutants. No differences were observed between left and right diaphragm in each genotypes. Scale: 2 mm. D: Dorsal, L: left, R: right, V: ventral. (**C**) Quantification of innervation percentage of muscle in each quadrant of diaphragm that is covered by the phrenic nerve in E18.5 wild-type and *Nova1/2* mutants. Using the phrenic nerve as reference, measurements of muscle length were taken from the insertion point of the phrenic nerve to the tip of the nerve (X), and from the tip of the nerve to the end of hemidiaphragm (Y), for the ventral and dorsal quadrants of left and right hemidiaphragms. The values indicate the ration of X/(X+Y), expressed as percentage ± standard deviation. \*\*p\<0.01 by t-test. Data are presented as mean ± SD.**DOI:** [http://dx.doi.org/10.7554/eLife.14371.025](10.7554/eLife.14371.025)

Motor innervation defects in the ventral diaphragm in NOVA2 dependent manner {#s2-6}
----------------------------------------------------------------------------

We previously reported that NOVA1/NOVA2 regulate the alternative splicing of the *agrin* Z exons ([@bib65]). Mice that lack both *Nova* family members fail to cluster AChR at neuromuscular junctions, including those of the diaphragm. Given the role for NOVA2 in axon guidance in the developing cortex ([Figure 6](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}, and [Figure 7](#fig7){ref-type="fig"}), we revisited the role of NOVA1 and NOVA2 on motoneuron axon guidance. The axons of peripheral motor neurons innervating the diaphragm muscle were visualized by immunostaining of neurofilaments at E18.5 ([Figure 8A](#fig8){ref-type="fig"}) and at E14.5 and E16.5 ([Figure 8B](#fig8){ref-type="fig"}) and the innervation percentage of muscle in each quadrant of diaphragm at E18.5 was quantified ([Figure 8C](#fig8){ref-type="fig"}). Although the motor innervation patterns and percentages of the dorsal diaphragm were normal in *Nova2-/-* and *Nova1/Nova2*-double knockout (dKO), those of the ventral diaphragm were severely abnormal with approximately 60--85% of the muscle uninnervated in either *Nova2-/-* and *Nova1/Nova2* dKO mice (p\<0.001). Similar abnormalities were observed in *Nova2-/-* and *Nova1/Nova2* dKO mice at E14.5 and E16.5 ([Figure 8B](#fig8){ref-type="fig"}). These innervation defects were specific to *Nova2*-deficient mice, as defects in ventral diaphragmatic innervation were never observed in wild-type or *Nova1-/-* mice. We cannot rule out a role of NOVA1 in the axon guidance of a subset of motoneurons given the slight decrease in ventral innervation in the Nova1/2 double-KO compared to the *Nova2-/-* mice. Nevertheless, taken together, these data demonstrate that in addition to what was observed in CC axons, *Nova2* is also essential for phrenic nerve innervation of the ventral but not dorsal diaphragm.

Auditory efferent innervation defect in NOVA2 dependent manner {#s2-7}
--------------------------------------------------------------

The inner ear is innervated by two types of fibers, afferent innervation consisting of both vestibular and cochlear (spiral ganglion neurons; [@bib54]) and from efferent fibers derived from rhombomere 4 of the hindbrain ([@bib68]). Efferents are guided by and extend along afferents to reach the sensory epithelia of the ear arriving at approximately the same time ([@bib25]; [@bib52]). Efferents are a unique population of ventral brainstem neurons derived from facial motoneurons that project to the inner ear in contrast to facial muscle fibers or glands ([@bib39]). Some transcription factors have been hypothesized to be relevant for guiding inner ear efferents ([@bib18]), however, essentially nothing is known about how these neurons diverge from facial motoneurons to selectively reach the ear to innervate hair cells and afferent processes ([@bib68]). Dye tracing analysis comparing with control mice at E14.5 ([Figure 9A,A'](#fig9){ref-type="fig"}) showed that *Nova2* ([Figure 9C,C'](#fig9){ref-type="fig"}) but not *Nova1* ([Figure 9B,B'](#fig9){ref-type="fig"}) was essential for proper progression of efferent growth along afferents. Moreover, although efferent neurons expressed both NOVA1 ([Figure 9---figure supplement 1I--J](#fig9s1){ref-type="fig"}) and NOVA2 ([Figure 9---figure supplement 1F--H](#fig9s1){ref-type="fig"}), *Nova1* by itself was not capable of maintaining the function. In the absence of both *Nova1/Nova2,* the efferents stalled when they reached vestibular ganglion neurons ([Figure 9D,D'](#fig9){ref-type="fig"}) while afferent fibers that also expressed both NOVA1 and NOVA2 ([Figure 9---figure supplement 1A--E, K](#fig9s1){ref-type="fig"}) reached the cochlea normally. Our data suggested that *Nova2* played a crucial role for efferent guidance relative to *Nova1,* but both cooperate for normal efferent fiber extension. Interestingly, vestibular efferent innervation which segregated from cochlear efferents at E14.5 ([@bib3]) was unaffected by the absence of *Nova1 or Nova2* alone (see *green* efferents reaching the posterior canal crista (PC) in [Figure 9B,C](#fig9){ref-type="fig"}) but was also completely stalled in *Nova1/Nova2* double knockouts (*green* label, [Figure 9D](#fig9){ref-type="fig"}). Postnatal *Nova2-/-* mice vestibular innervation was also normal (not shown).10.7554/eLife.14371.026Figure 9.NOVA2 expression is necessary for efferent innervation, targeting to the cochlea during embryonic development.(**A--D'**) Olivocochlear and vestibular efferents were labeled with lipophilic dye application to the crossing bundle in rhombomere 4 (*green*) and afferent (*red*) by dye application to the cochlear nuclei. This view shows the left ear viewed from medial. Anterior (**a**) is to the left and dorsal (d) is up. (**A**,**A\'**) wild-type mice spiral ganglion neurons (SGN) afferents reach the developing organ of Corti at E14.5 in the base and middle turn. Vestibular ganglia (VGN) project to the posterior canal crista (PC) and other vestibular sensory epithelia. (**B**,**B'**) Dye labeling of efferent fibers to the ear is comparable to wild-type in *Nova1-/-*mice and (**C**,**C\'**) shows reduced fiber growth in *Nova2-/- *mice (**D**,**D\'**). There is virtually no efferent fiber growth to the ear in *Nova1-/-, Nova2-/- *double knockout mice. Note that in D\' the afferent signal was reduced to reveal how far efferents are of the target (**E--L**). Efferent innervation (*green*) is shown in cochlea cryosections of Nova;YFPJ E18.5 mice. Nuclei are stained with DAPI (*blue*) and actin with Alexa-labeled Phalloidin (*magenta*). Apical (**E--H**) and basal (**I--L**) turns are shown. (**E**,**I**) wild-type (**F**,**J**) and *Nova1-/-* mice show equivalent axonal innervation, (**G**,**K**) *Nova2-/-* mice have reduced innervation, (**K**) especially in the base. (**H**,**L**) *Nova1-/-, Nova2-/- *double knockout show no efferent innervation of the cochlea. *Arrowhead* shows approximate location of OHC rows (white) or IHC (orange). Some auto-fluorescence is visible in L. Inset shows nuclear stained (DAPI). Scale bars: 100 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.14371.026](10.7554/eLife.14371.026)10.7554/eLife.14371.027Figure 9---figure supplement 1.NOVA1 and NOVA2 expression in spiral ganglion (SG) and in superior olive neurons but not in hair cells.(**A**) Sagittal sections of Rosa26 (R26R); *Nova2*-/- mice at six month of age. β-gal staining shows that the expression of *Nova2* was switched on during development in the spiral ganglion (SG) were the soma of the afferent innervating neurons are located (**B**) The enlarged organ of *Corti* area (*dashed line* in **A**) shows no expression of *Nova2* in the cochlea, including IHC (*red arrowhead*) and OHC (*green arrowhead*). (**C**) Control Rosa26 (R26R); *Nova2+/+* mouse shows no staining. (**D**) Immunostaining of P20 SG cells with an antiserum that recognizes NOVA1 and NOVA2 (**E**) showing the expression of NOVA1 in *Nova2-/- *mouse and demonstrating that NOVA1 and NOVA2 are expressed in SG. (**F**) In addition there is label in the soma of the medial olivococlear (MOC) neurons projecting efferent axons to the OHC which are located in the Medial superior olive (MSO) and lateral olivocochlear (LOC) neurons projecting axons the afferents below the IHC whose somas are located in the lateral superior olive (LSO) of the brainstem. (**G**) Enlarged area showing stained neuronal soma in MSO and LSO. (**G--I**) Immunostaining of a comparable section at P14 (**H**) wild-type section stained with C-16 a NOVA2 specific antibody. (**I--J**) *Nova2-/- *section stained simultaneously with C-16 antibody (showing unspecific background) and (**I**) with an antiserum that recognizes NOVA1 and NOVA2 showing the expression of NOVA1 in the superior olive. (**K1**--**K3**) Total RNA was extracted from micro dissected organ of *Corti* (dashed line rectangle), analysed by qPCR and normalized by actin. The plots show *Nova1* and *Nova2* gene expression relative to the expression of *Nova1* in control P7 mouse at (**K1**) P7 and (**K2**) P14. (**K3**) the expression of the hair cell marker Myosin 7a (*Myo7a*) is shown at the indicated time points as a control. The reduced expression at P18 reflects problems in the dissection due to increased calcification. There is no apparent problem at P14, suggesting that the reduction in NOVA1 and NOVA2 expression at P14 is a biological phenomenon that probably reflects pruning of innervation. V: motor trigeminal nucleus, VII: Facial Nucleus. Scale bars; 200 μm (**A**), 50 μm (**B**) 10 μm (**H**--**J**). \*p\<0.05, \*\*p\<0.01 (n = 3, t test). Data are presented as mean ± SE.**DOI:** [http://dx.doi.org/10.7554/eLife.14371.027](10.7554/eLife.14371.027)

The cochlea has a tonotopic map where the sensory hair cells at each position along the organ are most sensitive to a particular frequency, forming a continuous gradient from high frequency in the base to low frequency in the apex ([@bib32]; [@bib34]; [@bib46]). Dye tracing analysis showed that the loss of efferent innervation was frequency specific; it was almost completely lost in the base of the *Nova2-/-* cochlea and only partially lost towards the apex (compare [Figure 9A' and C'](#fig9){ref-type="fig"} ). A more detailed analysis was possible at E18.5 ([Figure 9E--L](#fig9){ref-type="fig"}), when the medial olivocochlear (MOC) efferent axons expand through the tunnel of *Corti*, prior to their reaching the outer hair cells (OHC) at P2 and establishing functional synapses at P7 ([@bib68]). These axons stained strongly with the Thy-1, YFPJ line that also has high expression in motor neurons, demonstrating the motor origin of auditory efferents. Thy-1 positive axons reached the inner hair cells (IHC) at E18.5 in control ([Figure 9E,I](#fig9){ref-type="fig"}) and *Nova1-/-* ([Figure 9F,J](#fig9){ref-type="fig"}) mice but this innervation was reduced in the *Nova2-/-* ([Figure 9G,K](#fig9){ref-type="fig"}) mice, and this was especially evident in the base ([Figure 9K](#fig9){ref-type="fig"}). In the absence of both *Nova1/Nova2* there were no labeled axons reaching the cochlea ([Figure 9H,L](#fig9){ref-type="fig"}), showing that efferents remain stalled. Imaging of efferent innervation at the onset of hearing (P14) showed a clear reduction in axons reaching IHC and specially OHC in the base when comparing *Nova2-/-* mice ([Figure 10C,D,G,H](#fig10){ref-type="fig"}) to controls ([Figure 10A,B,E,F](#fig10){ref-type="fig"}). At this age we also found a reduction in efferent synapse formation as demonstrated by reduced labeling with the pre-synaptic marker synaptophysin (*blue* label at the base of IHC and OHC). Whole mount apical cochlea (Segment 2, see map in [Figure 10O](#fig10){ref-type="fig"}) at P10 showed a reduction in axons reaching IHC and an almost complete absence of axons reaching OHC ([Figure 10K,L](#fig10){ref-type="fig"}) compared to controls ([Figure 10I,J](#fig10){ref-type="fig"}).10.7554/eLife.14371.028Figure 10.Efferents innervation defect and hearing impairment in postnatal Nova2-/- mice.(**A--H**) Cochlea cryosections immunostaining of in *Nova2-/-*;YFPJand control *Nova2+/+*;YFPJ P14 mice. The images show reduced efferent axons in *green* (YFP, see *arrows*), afferent neurofilaments (NF200) in *red* and phalloidin (Phall) labeling of actin-rich hair bundles in *magenta*. The presynaptic marker synaptophysin (syn) in *blue*, shows a reduction of functional efferent innervation. (**A--F**) control mouse, (**C--H**) *Nova2-/-*;YFPJ mouse. (**A--D**) Apical or (E-H) Basal organ of Corti. (**I--L**) Cochlea apical turn segment 2 (see below) whole mount preparations immunostaining of (**K, L**) *Nova2-/-*;YFPJ and (**I,J**) *Nova2+/+*;YFPJ P10 mice. The images show reduced efferent axons in *green* (YFP), NF200 in *red* and Phall in *blue*. (**A--L**) *Arrowheads* show approximate location of OHC rows (*white*) or IHC rows (*orange*). (**O**) Representation of the dissection map of the cochlea indicating segments 1--5 and the approximate localization along the length of the cochlea. (**M**) The thresholds of the auditory brainstem response (ABR) to pure-tone stimuli ranging from 10 to 80 dB SPL are increased significantly in *Nova2-/-* mice (n = 4--5 for each frequency) compared to wild-type mice (n = 5--6) at P21-P22. (**N**) The distortion-product otoacoustic emissions (DPOAEs) at 2f~1~-f~2~ measured at 55, 65 and 75 dB SPL show significant differences between wild-type mice (n = 4) and *Nova2-/-* animals (n = 4) at P21-P22. The noise floor (NF) that was measured simultaneously is also shown for both groups. The approximate acoustic representation of segments 2--4 of the dissected cochlea are shown over each plot and segment 2 is overshadowed in *gray*. Scale bars: 50 μm. \*p\<0.05.**DOI:** [http://dx.doi.org/10.7554/eLife.14371.028](10.7554/eLife.14371.028)10.7554/eLife.14371.029Figure 10---figure supplement 1.Reduced efferent innervation and increased afferent innervation to the apex of the *Nova2-/-* mice cochlea.(**A--C**) Quantitation of efferent neuronal axons by colorimetric detection of the enzyme acetyl cholinesterase (AChE) in the cochlear apex of (**B**,**B'**) *Nova2-/-* and control (**A**,**A'**) wild-type mice. Representative images are shown. Green arrows indicate the 3 rows of OHC and red Arrow the row of IHC. These preparations were done in non-decalcified cochlea and only the apex could be preserved after dissection. (**B**) Plot showing quantification of the colorimetric signal. Heterozygote *Nova2+/-* mice were included in the plot to show that defect is dependent on the dose of NOVA2 expressed (n = 4). P15-P25 mice were used \*\*p\<0.01. (**D**,**E**) Cochlea whole mount and (**D'**,**E'**) Cryosections immunostaining in wild-type and *Nova2-/-* P20 mice. The images show apparent increased afferent innervation staining (NF200, *red*). Hair cells are labeled with a *MYOVI* antibody (*green*) and hair bundles with Phall. (*magenta*). (**F--I**) Afferent innervation to the IHC was quantified by counting individual ribbon synapses stained with CTBP2 antibody at P18. (**F--H**) wild-type (**G--I**) *Nova2-/-*, (**F**,**G**) segment 2, apex and (**H**,**I**) segment 4, apex (see [Figure 10-O](#fig10){ref-type="fig"}). (**F'--I'**) Respective amplified afferent IHC synapses. (**J**) A total of 30 wild-type and 44 *Nova2-/-* cells from 2 mice of each genotype were quantified. Each dot in the plot represents 2--5 averaged cells. The figure shows the approximate location of cells from segment 1--4 along the% length of the cochlea from apex to base on the lower x axes and the approximate frequency representation in the upper x axes. The number of dots (synapses) per cell was quantified by counterstaining with MYOVI which allows to outline the IHC perimeter. \*\*p\<0.01.**DOI:** [http://dx.doi.org/10.7554/eLife.14371.029](10.7554/eLife.14371.029)

These defects were also evident in apical cholinergic innervation ([@bib12]; [@bib53]) after the onset of hearing (P15-P25; [Figure 10---figure supplement 1A--C](#fig10s1){ref-type="fig"}). At these stages, we were able to demonstrate that the loss of axonal innervation was functionally significant, as assessed by auditory brainstem responses (ABRs) and distortion products otoacustic emissions (DPOAEs) recordings ([Figure 10M--N](#fig10){ref-type="fig"}) In addition, an apparent increase in afferent innervation was found in *Nova2-/-* mice by neurofilament immunodetection ([Figure 10A--L](#fig10){ref-type="fig"} and [Figure 10---figure supplement 1D--E](#fig10s1){ref-type="fig"}). The difference was significant in the apex as determined by quantitation of IHC ribbon synapses ([@bib55]) ([Figure 10---figure supplement 1F--J](#fig10s1){ref-type="fig"}). Taken together, these data demonstrate a role for NOVA in cochlear innervation, efferent pathfinding, and normal hearing function in vivo.

Discussion {#s3}
==========

In the present work, we provide evidence for a novel and unique role for the tissue specific splicing regulator NOVA2 as an axon pathfinding modifier in cortical CC axons, motoneuron, and auditory efferents. In prior studies, integration of transcriptome-wide HITS-CLIP analysis, exon junction microarray data sets, and bioinformatics led to the identification of a large set of NOVA1/2 RNA functional interaction sites and major biological pathways which NOVA1/2 orchestrates in vivo ([@bib49]; [@bib76]; [@bib78]; [@bib88]). Given identical binding characteristics in shared transcripts (e.g. *Agrin*, others in [Figure 2](#fig2){ref-type="fig"}), we infer the following: 1) specificity is determined primarily by biochemical interactions: kD of NOVA KH domains binding to accessible YCAY motifs; this might include differential levels of NOVA1/NOVA2 expression within a cell; 2) differential binding is a function of differences in cell expression and/or differences in cell biology (e.g. subcellular distribution of NOVA1 and NOVA2). Evidence for differences in cell expression is clear in the cortex. Differences in actions within cells such as motoneurons that express both NOVA1 and NOVA2 isoforms could arise from different levels of NOVA1 and NOVA2 within the neurons, or due to differential localization of NOVA1 and NOVA2 within the motoneuron, as suggested by the differences in CLIP binding (intron versus 3' UTR) of the two proteins ([Figure 2F](#fig2){ref-type="fig"}). The development of single cell-type CLIP would be able to address this issue. Prior genomic and biochemical studies have found no actions that were unique to either NOVA1 or NOVA2 paralogues. The present study identifies NOVA2 as playing a unique role in axonal pathfinding in embryonic development by combining histological analysis with genome wide NOVA1 and NOVA2 specific HITS-CLIP and RNA-seq analysis in *Nova1-/-* and *Nova2-/-* mice. These data build upon previously identified roles for NOVA1 and NOVA2 in early development as modifiers of neuronal migration in late-generated cortical neurons and Purkinje neurons through control of splicing of *Dab1* exon 7b/7c ([@bib87]), for *Nova1/Nova2* as essential factors for AChR clustering at the NMJ through the regulation of *Agrin* Z exons ([@bib65]), and for *Nova2* in the induction of long term potentiation of slow inhibitory, but not excitatory, post synaptic potential currents after coincidence detection in CA1 hippocampal neurons ([@bib33]). The current study provides the first evidence that the formation of corpus callosum in brain, proper innervation of ventral diaphragm, and efferent innervation to the cochlea at developing embryonic stage all require specific actions mediated by NOVA2 ([Figure 11](#fig11){ref-type="fig"}).10.7554/eLife.14371.030Figure 11.Model summarizing a unique role for NOVA2 in the consequence to neuronal axon guidance and outgrowth.The results of HITS-CLIP and RNA-seq analysis combined with histological analysis in *Nova2-/-* mice suggest a model that NOVA2 starts to act on an axon guidance regulatory cascade during neural differentiation in the neurons located on cortical plate. The breakdown of NOVA2-mediated RNA regulation results in the collapse of the normal axon guidance/outgrowth properties in either/both the neuron extending axon or/and the neuron expressing axon guidance cue.**DOI:** [http://dx.doi.org/10.7554/eLife.14371.030](10.7554/eLife.14371.030)

Immunohistochemical and DiI tracer analysis showed that *Nova2* deficiency results in severe ACC ([Figure 6](#fig6){ref-type="fig"}, and [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). There are over 50 mouse genes known to be required for the formation of the corpus callosum (reviewed in [@bib7]; [@bib20]). NOVA2 HITS-CLIP and RNA-seq analysis revealed that 11 NOVA2 target alternative splicing events on 9 genes (*Dcc, Robo2, Epha5, Slit2, Ank2, Dclk1, Enah, Cask, Ptprs*) intersected with the genes associated with mouse ACC phenotypes and human ACC syndromes ([Figure 6---figure supplement 3](#fig6s3){ref-type="fig"}), suggesting that the ACC phenotype in *Nova2*-/- mice may be caused by splicing dysregulation of multiple coordinately NOVA2-regulated transcripts, consistent with previous observations that NOVA proteins regulate subsets of transcripts that mediate coordinate biologic functions ([@bib76]). Given that *Netrin-1* null mice and *Dcc* null mice shows similar ACC phenotype to *Nova2* null mice ([@bib23]; [@bib67]), we tried to rescue the ACC phenotype with the DCC-long isoform, that is decreased in the cortex of *Nova2*-/- mice, by *in utero* electroporation (data not shown). The expression of DCC-long (long isoform of exon 17) isoform in cingulate cortex at E14.5 was not sufficient to form the commissure corpus callosum, indicating that the DCC-long isoform was not sufficient to rescue the ACC phenotype, and suggesting the possibility that the ACC phenotype in *Nova2*-/- mice either does not involve the DCC-long isoform or is caused by the dysregulation of multiple transcriptomes.

We found that in the cortex, NOVA2 regulates alternative splicing events of two netrin receptors: *Dcc* exon 17 and *Neo1* exon 27 in developmentally regulated manner ([Figure 4](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}, and [Figure 5](#fig5){ref-type="fig"}). In the spinal cord, *Dcc* exon 17 is regulated by NOVA1/2 and required for the spinal commissural neuron development (see accompanying paper by Leggere et al.). Recent structure analysis of netrin-1/NEO1 and netrin-1/DCC-short (short isoform of exon 17) revealed that netrin-1/NEO1 form a 2:2 heterotetrameric netrin-1/NEO1 complex and netrin-1/DCC-short have a continuous netrin-1/DCC assembly ([@bib84]). Netrin-1 recognizes the fourth and fifth fibronectin type III domains (termed FN4 and FN5, respectively) of both NEO1 and DCC. Interestingly, the NOVA2-regulated *Dcc* exon 17 is located in the linker region between the FN4 and FN5 domains, and this splicing switch from DCC-short to DCC-long isoform is enough to support the architectural switch of netrin-1/DCC complex from the continuous assembly to the 2:2 assembly ([@bib84]). This suggests that NOVA2-dependent splicing regulation results in architecturally distinct netrin-1/DCC complexes that elicit distinct downstream signaling. Changes in NOVA2-dependent regulation of *Dcc* exon 17 splicing during development ([Figure 5](#fig5){ref-type="fig"}) further indicate that NOVA2-regulated splicing controls the ability of cortical and spinal neurons to utilize distinct netrin-1/DCC assemblies to respond to a variety of cellular demands.

NEO1, another member of the *Dcc* family, shares \~50% amino acid identity with DCC ([@bib80]) and has four known alternative splicing sites. The NEO1 extracellular region is a receptor for repulsive guidance molecule (RGM) family molecules in addition to netrins. Upon ligand binding to the extracellular domain of NEO1 and DCC, their intracellular domains can activate multiple downstream signal transduction pathways, that modulate chemotropic axon guidance ([@bib1]). The inclusion of *Neo1* exon 27 inserts a 53 amino acid sequence into the intracellular region. Inclusion is increased in E18.5 *Nova2-/-* cortex, suggesting that NOVA2-dependent alternative splicing of *Neo1* exon 27 regulates downstream signal transduction. It is well-established that DCC receptors mediate chemo-attraction upon netrin-1 binding, while the UNC5 receptor alone or heterodimerized with DCC elicits chemo-repulsive activity in neuronal tissues ([@bib31]). Interestingly, UNC5B interacts with NEO1 as a co-receptor for RGMa and associates with leukemia-associated guanine nucleotide exchange factor (LARG, also termed as ARHGEF12) to mediate the signal transduction leading to growth cone collapse ([@bib29]). Although the abundance of *Arhgef12* RNA in cortex was comparable between E18.5 wild-type and *Nova2-/-* mice (log~2~FC = 0.10, FDR = 0.78), *Arhgef12* exon 4 inclusion was significantly increased in *Nova2-/-* mice ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}), suggesting the possibility that NOVA2 modulates RGM signal transduction mediated by NEO1, UNC5b, and ARHGEF12 through coordinate regulation of alternative splicing of those RNAs.

Interestingly, exon 7--8 deletion of *Srrm4/nSR100* gene, an alternative splicing regulator, mice shows partial ACC phenotype and neurite outgrowth defect in diaphragm ([@bib62]) in addition to hearing defects (see below), indicating that alternative splicing regulation mediated by RBPs (e.g. NOVA2, SRRM4/nSR100) is required for the formation of corpus callosum and neurite outgrowth into diaphragm.

Our analyses were focused on axon guidance related genes but do not rule out the possibilities that axonal pathfinding defect phenotypes in *Nova2*-/- were caused by deficits of multiple biological processes. Several relevant processes were enriched in GO and KEGG pathway analysis, including protein modification, phosphorylation, cellular protein metabolic process, synaptic transmission, chromatin modification, adherens junction, and cell morphogenesis involved in neuron differentiation. Our previous work has showed that the proliferation of cortical neural progenitor cells was not disrupted in *Nova2-/-* ([@bib87]). RNA-seq data showed that the transcriptome abundance of the neuronal differentiation markers were comparative between wild-type and *Nova2*-/- mice ([Figure 3---source data 2](#SD2-data){ref-type="supplementary-material"}), indicating that the differentiation from neuronal progenitor to neuron is comparable between wild-type and *Nova2*-/- mice.

Despite the important role of alternative splicing in the formation of the cochlear tonotopic gradient ([@bib59]; [@bib64]; [@bib56]) and in hair cell development and function ([@bib43]; [@bib7]; [@bib81]) to date only two alternative splicing factors have been implicated in hearing: *Srrm4/nSR100* ([@bib58]) and *Sfswap* ([@bib57]). Both are expressed in hair cells necessary for the development of the sensory epithelium, in contrast with *Nova1* and *Nova2*, which are the first neuron-specific splicing factors described to regulate cochlear innervation.

Interestingly auditory efferents are a ventral population of rhombomere 4 facial brachial motoneurons that segregate during development ([@bib39]) and while facial innervation is normal, the ventral auditory efferents are selectively affected in the *Nova2-/-* mice ([Figure 9A--D](#fig9){ref-type="fig"} and data not shown). This specificity is similar to the observation that dorsal motoneuron innervation of the diaphragm is normal while ventral innervation ([Figure 8](#fig8){ref-type="fig"}) is affected in the *Nova2-/-* mouse, suggesting a more general ventral specialization of axonal guidance regulation by NOVA2. These observations are reminiscent of those seen with defects in GATA-3 innervation of facial motor neurons ([@bib39]) and dorsal/ventral pathfinding of limb motoneurons regulated by *EphA4* ([@bib30]), suggesting the possibility of an integrated role for NOVA2 in dorsal/ventral axonal pathfinding.

To assess OHC function we measured DPOAEs ([@bib50]) in *Nova2-/-* mice. There was a significant reduction in DPOAEs in the apex of *Nova2-/-* mice cochlea (Up to 10 dB SPL, [Figure 10N](#fig10){ref-type="fig"}) where a significant reduction in cholinergic innervation was also found ([Figure 10---figure supplement 1A--C](#fig10s1){ref-type="fig"}). Nevertheless the reduction in efferent innervation is comparatively more severe in the base of the cochlea ([Figure 9](#fig9){ref-type="fig"} and [10A--H](#fig10){ref-type="fig"}) suggesting that OHCs sensitive to low frequency sounds are more dependent on *Nova2* controlled efferent innervation. Direct testing of efferent function by electrical activation of these nerves has been shown to reduce the baseline DPOAE intensity ([@bib47]; [@bib79]). Preliminary testing in *Nova2-/-* mice showed that this inhibitory function was not affected (Stéphane S Maison, personal communication), suggesting that the residual efferent innervation was able to sustain the function of further reducing the DPOAEs.

Only an indirect mouse model of efferent innervation defect has been available to date: a mutation in the α9α10 hair cell nicotinic receptor ([@bib70]) in which the DPOAEs threshold levels are reduced by approximately 7--14 dB SPL (a reduction in 10 dB SPL is perceived approximately as half the intensity). In addition, the reduction in DPOAEs found in the *Nova2-/-* mice could explain the ABR threshold elevation at the same frequency range ([Figure 10M](#fig10){ref-type="fig"}) ([@bib69]; [@bib48]). The opposite possibility, that the defect evidenced by ABRs is responsible for the reduction in DPOAEs is unlikely since it has been reported that even with 80% loss of IHC (with intact OHC) the DPOAEs are only reduced by 10--20 dB SPL ([@bib73]). It has also been recently shown that afferent innervation to the OHC has no effect on DPOAEs ([@bib27]). Despite the reduction in ABRs which measure afferent pathway function, we found an increase in afferent innervation ([Figure 10A--L](#fig10){ref-type="fig"}) quantified by synaptic ribbon count in *Nova2-/-* mice ([Figure 10---figure supplement 1E--J](#fig10s1){ref-type="fig"}) although further study will be necessary to determine if this synapses are functional. Increase in afferent innervation could be a compensatory mechanism to decreased lateral olivocochlear (LOC) efferents, which form synapses on IHC afferents, or a direct effect of the loss of *Nova2* expression in afferent neurons through an ephrin-dependent pathway ([@bib15]). An interesting possibility is that the transient synapses formed between MOC efferents and IHC during development ([@bib68]) have an important role in IHC development that is impaired in *Nova2-/-* mice.

Taken together, our observations suggest that protein/RNA diversity provided by NOVA2-mediated RNA regulation is required for proper axon pathfinding and formation of complex synapses/neural networks, particularly in dorsal/ventral choices, and that alternative splicing switches mediated by NOVA2 may regulate key developmental steps in mammalian biology and pathogenesis of neurological diseases.

Material and methods {#s4}
====================

Generation of *Nova2* null mice {#s4-1}
-------------------------------

Two fragments from the *Nova2* genomic locus of 2.2 and 6 kb, flanking a 1.5 kb DNA fragment harboring the exon containing the initiating methionine, were cloned into a targeting vector. An *IRES-Cre-FRT-Neo-FRT* targeting cassette was inserted into the *Nova2* locus upstream of the initiator ATG in the first known coding exon of the *Nova2* gene. Linearized targeting vector plasmid was electroporated into ES, and G418-resistant clones (150 ug/mL G418 for 24 hr) harboring homologous recombinants were screened by Southern blot with a 5' *Nova2* genomic probe and injected into mouse blastocysts to produce germline transmitted chimeras. The neomycin cassette was excised by breeding germline-transformed mice with transgenic animals expressing Flp recombinase under the control of the CMV promoter. The original *Nova2+/-* (and *Nova1+/-*) mice obtained in a B57B/6 background were backcrossed for 10 generations to CD-1 and FVB strains and to the thy1-YFP line J (YFPJ) strain (Jackson labs Stock 003709) which has high expression of YFP in motor neurons ([@bib24]) or crossed to the R26R strain (Jackson lab stock 003309) for *Nova2* tissue-wide expression analysis. Most experiments were done in CD-1 background, but mice in the inbred FVB background showed no phenotypic differences. FVB mice were used for the hearing tests reported here because they present normal hearing thresholds ([@bib37]) and less inter individual differences. All procedures in mice were performed in compliance with protocols approved by the Institutional Animal Care and Use Committee (IACUC) of the Rockefeller University or the Comité de déontologie de l'expérimentation sur les animaux (CDEA) of the Univeristy of Montreal.

Antibodies {#s4-2}
----------

Primary antibodies used for immunohistochemistory and western blot were as follows; goat anti-NOVA2 (C-16) (sc-10546, Santa Cruz), rabbit anti-NOVA1 \[EPR13847\] (ab183024, abcam), human anti-pan NOVA (anti-Nova paraneoplastic human serum), rabbit anti-PTBP2 ([@bib61]), rat anti-L1 (MAB5272, Millipore), goat anti-TAG1/Contactin-2 (AF4439, R&D systems), goat anti-NetrinG1a (AF1166, R&D systems), rabbit anti-NURR1 (M-196) (sc-5568, Santa Cruz), rabbit anti-neurofilament (AB1981, Chemicon), mouse anti-NF200 (N5389, SIGMA), mouse anti-ctbp2 (612044, BD), rabbit anti-myoVI (sc-50461, Santa Cruz), and goat anti-neuropilin-1 (AF566, R&D systems). Anti-NOVA1 and anit-NOVA2 antibody specificity for immunohistochemistory and immunoprecipitation was confirmed ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}).

Immunohistochemistory {#s4-3}
---------------------

E16.5, E18.5 mice brains were fixed with 4% praraformaldehyde (PFA)/PBS at 4 degrees overnight, and sequentially replaced to 15% sucrose/PBS and 30% sucrose/PBS at 4 degrees for cryo-protection, then embedded in OCT compound. Frozen brains were sliced into 80 μm thick sections on a cryostat (CM3050S, LEICA). Brain sections and whole embryos fixed with 4% PFA/PBS were subjected to floating or whole-mount immunohistochemistry. These samples were washed three times with PBS at room temperature (RT), incubated with 0.2% Triton X-100/PBS at R.T., blocked with 1.5% normal donkey serum (NDS)/PBS at RT, and then incubated overnight at 4 degrees with primary antibodies or Alexa-dye conjugated phalloidin in 1.5% NDS/PBS followed by incubation with Alexa 488, 555, or 647 conjugated donkey secondary antibodies (1:1000) in 1.5% NDS/PBS. Images of immunostained specimens were collected by BZ-X700 (KEYENCE), fluoscence microscopes Axioplan 2 (Zeiss), or an inverted TCS SP8 laser scanning confocal microscope (LEICA) at The Rockefeller University Bio-Imaging Resource Center.

Cochlea tissue processing and imaging {#s4-4}
-------------------------------------

Embryos were obtained by C-section of time-mated dams and fixed by overnight immersion in 4%PFA. Postnatal mice were intracardialy perfused with 4% PFA, cochleae immediately removed and perfused through the round window with a 1 ml syringe. After post-fixation 2:30 hr at 4°C cochleae were washed in PBS, directly dehydrated in 30% sucrose at 4°C or previously decalcified for 24--48 hr in 120 mM EDTA in PBS. For beta-galactosidase expression analysis the decalcified cochleae were perfused through the round window with M-1 embedding matrix (Thermo Scientific) and frozen in a block of the same matrix, 40 µm cryosections were incubated in staining solution (4 mM potassium ferricyanide, 4 mM potassium ferrocyanide, 1 mg/ml x-gal) dissolved in wash buffer (2 mM magnesium chloride, 0,01% sodium deoxycholate, 0,1% NP40 and 0.2 mM buffer phosphate pH 8.0) overnight at 37°C, washed in wash buffer 3 hr at 4°C, post-fixed again in 4% PFA and washed in PBS before mounting. For AChE staining the non-decalcified cochleae were dissected by carefully chipping the bone away and incubated in a solution containing 0.5 mg/ml acetylcholine iodide as explained elsewhere ([@bib82]). For whole mount immunostainings the decalcified cochleae were dissected cutting into half turns (See [Figure 10O](#fig10){ref-type="fig"}), permeabilized and blocked in 0.1% TX100, 5% donkey serum in PBS. Primary and secondary antibodies were incubated sequentially 24 hr at 4°C. Washes were done in 0.05% TX100. For cryosections the decalcified cochleae perfused through the round window with M-1 embedding matrix (Thermo Scientific) or the fixed embryos were cut into 14--20 µm sections, permeabilized and blocked in 0.1% Triton-X100, 5% donkey serum in PBS. Primary antibodies were incubated 24 hr at 4°C and secondary antibodies for 2 hr at room temperature. Washes were done in PBS. Alexa labeled Phalloidin (1:100) was added to the secondary antibody mix. Images were collected using a Zeiss LSM 510 confocal microscope at The Rockefeller University Bio-Imaging Resource Center and a Zeiss LSM 700 confocal microscope at the IRIC core of the University of Montreal.

Axon tracing {#s4-5}
------------

For DiI trace analysis, DiIC18(3) crystal (D3911, molecular probes) were placed in cingulate cortex or lateral neocortex of P0 brain. After 8--21 days at 37 degrees in 4% PFA/PBS to allow dye diffusion, samples were cryo-protected with 30% sucrose/PBS at 4 degrees, embedded in OCT compound, and cut into 100 μm sections on cryostat. Counterstaining was with 1 μg/mL DAPI (4',6-Diamidino-2-phenylindole dihydrochloride). The images of immunostained specimens were collected by a fluoscence microscope Axioplan 2 (Zeiss). Inner ear afferents and efferents were labeled with lipophylic (NeuroVue) dyes (Molecular Targeting Technologies; MTTI). These dyes were placed into specific areas for selective labeling of nerve fibers ([@bib26]; [@bib19]) Dyes were placed into the cerebellum and the alar plate of rhombomere 2 to label the afferent fibers to the ear. Dye was also placed into the basal plate of rhombomere 4 for efferent nerve labeling. The preparations were then incubated in 4% PFA at 36 degrees C for three days. After dye diffusion the ear was dissected out and placed on a glass slide with glycerol and a cover slip on top to be imaged with a Leica SP5 confocal microscope.

Western blot and semi-quantitative RT-PCR {#s4-6}
-----------------------------------------

Western blotting and RT-PCR analyses were performed as described elsewhere ([@bib87]). For quantification, three biological replicates were used and quantified from obtained images by using ImageJ free software (<http://rsb.info.nih.gov/ij/index.htm>l).

Hearing tests {#s4-7}
-------------

ABRs were recorded from deeply anesthetized mice. The positive needle electrode was inserted subdermally at the vertex, the negative electrode was placed beneath the pinna of the left ear, and the ground electrode was located on the hind leg. ABRs were evoked by tone bursts ranging from 4--64 kHz and were produced by a closed-field electrostatic speaker connected to a driver (EC‑1 and ED‑1; Tucker-Davis Technologies). The 5 ms tone bursts were presented 33.3 times per second; their 0.5 ms onsets and offsets were tapered with a squared cosine function. The speaker's audio output was transmitted into the ear through a custom acoustic assembly. Sound-pressure levels were measured with a calibrated microphone and preamplifier connected to a conditioning amplifier (4939‑A‑011 and 2690‑A‑0S1, Brüel and Kjær). The response was amplified x10,000 and bandpass filtered at 0.3‑3 kHz (P55, Natus Neurology Inc.). The amplified response was then digitally sampled at 10 μs intervals with a data acquisition device (PCIe-6353, National Instruments) controlled by custom software (LabVIEW 2010, National Instruments). The responses to 1000 bursts were averaged at each intensity level to determine the threshold, defined as the lowest level at which a response peak was distinctly and reproducibly present. For each frequency, sound-pressure level was decreased from 80 dB SPL in 5 dB steps until threshold was reached. DPOAEs were then elicited with an acoustic coupler that allowed for recording ear-canal sound pressure levels via a probe tube concentrically situated within the common sound-delivery tube. The acoustic coupler consisted of two electrostatic speakers (EC‑1, Tucker-Davis Technologies) to generate primary tones and a miniature microphone (EK‑23103, Knowles) to measure ear-canal sound pressure (coupler from Mike Ravicz, EPL, Eye&Ear inf, Boston). The speakers and the microphone were both calibrated using the calibrated microphone described above. The 2*f*~1~ − *f*~2~ distortion product was measured with *f*~2~ = 6--54 kHz, *f*~2~/*f*~1~ = 1.2, and L~1~ = L~2~ = 55‑75 dB SPL. The acoustic signal was amplified by a preamplifier (ER‑10B+, Etymotic Research) and the sound pressure measured in the ear canal was digitally sampled at 10 μs intervals with the data-acquisition system described above. Each frequency pair was presented for 1 s. After fast Fourier transforms had been computed and averaged over ten consecutive traces, the amplitudes of the 2*f*~1~ − *f*~2~ distortion product and the surrounding noise floor (+/- 100 Hz of 2*f*~1~ − *f*~2~) for each frequency pair were determined, a procedure requiring 17 s of data acquisition and processing time.

HITS-CLIP {#s4-8}
---------

NOVA1 and NOVA2 CLIP was performed on E18.5 wild-type cortex using three biological replicates, as described elsewhere ([@bib49]). High-throughput sequencing was performed at the Rockefeller University Genome Resource Center. Sequence tags were aligned to the mouse genome (mm9) by novoalign. Unique tags were collected by eliminating PCR duplicates.

RNA-seq and analysis {#s4-9}
--------------------

E18.5 mouse cortex RNA from wild-type and *Nova2-/-* littermate and E18.5 mouse cortex and midbrain/hindbrain RNA from wild-type and *Nova1-/-* littermate (three biological replicates for each genotype) was prepared using Trizol (ambion) and ribosomal RNA was removed from 1 μg RNA using Ribo-Zero rRNA removal Kit (epicentre). Standard RNA-seq libraries were prepared using TruSeq RNA Sample Preparation Kit v2 (illumina) following manufacturer's instructions. High-throughput sequencing was performed on Hi-seq 2500 (illumina) to obtain 125 nucleotide paired-end reads at New York Genome Center. Reads were aligned to the mouse genome (mm10) using OLego ([@bib83]). The downstream splicing analysis was performed as described previously ([@bib85]) and then liftovered to mm9. Differential expression analysis was performed with the R package edgeR ([@bib63]) available on Bioconductor 3.0 ([@bib28]).

Accession numbers {#s4-10}
-----------------

RNA-seq and HITS-CLIP data have been deposited in GEO under accession number GSE69711 (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE69711>).
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"NOVA2-mediated RNA regulatory networks are required for axonal pathfinding during development\" for consideration by *eLife*. Your paper has been reviewed by three reviewers, one of whom is a member of the Board of Reviewing Editors, and it was also evaluated by a Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

All three of the reviewers agree that the strength of the paper lies in finding that Nova2 uniquely regulates alternative splicing of axon guidance-related genes in cortical development, that the Nova2 null mice have interesting axonal defects in cortex, spinal cord, and brain stem. All also agree that the quality of the molecular data is excellent.

The major limitations are: 1) there is no causal link between any of the splicing defects and the phenotypes, including agenesis of the Corpus Callosum; 2) the authors do not even attempt to relate their molecular findings to the over 60 genes already known to play a role in development of the Corpus Callosum; they do not credit some important relevant papers and do not look at other potential candidates that emerged from their GO analysis; and lastly there are no data as to how the alternatively spliced variants differ in activity.

While the reviewers see these limitations, they have decided that together with the Chen et al. paper, the two manuscripts report on related and biological observations.

That said there are several things outlined below that we do hope you can address in a revision. The full reviews are also included at the end of this summary.

The issues that must be addressed:

1\) The loss of the corpus callosum is a severe and convincing phenotype in *Nova2* mutants. The authors focus their discussion of this phenotype almost entirely on the netrin-1/DCC signaling pathway for the good reason that Nova2 regulates the alternative splicing of two netrin receptors, DCC and Neo1. However, they do not test this directly. The link between the splicing target and the phenotype would be significantly strengthened by the addition of data testing whether DCC or Neo1 can rescue the ACC phenotype. These would be challenging but valuable experiments.

Without the DCC or Neo1 rescue experiments, the authors should widen the discussion about the possible targets affected in the Nova2A mutant that could give rise to the agenesis phenotype. There are around 60 mouse genes known to be required for the formation of the corpus callosum (e.g. Paul et al. 2007; Donahoo and Richards, 2012) so it would valuable to try to establish how many of these identified genes are targets of Nova2. How many of these 60 genes are present in the Nova2A target data? Loss of Neuropilin1, for example, gives rise to ACC (Lim et al. 2015) and the EphB1 and EphB2 intracellular signalling domains are required for the formation of the CC (Robichaux et al. 2015). These two studies also report the loss of the anterior commissure in addition to the CC. Does the *Nova2* mutant show a defect in axons crossing the AC?

2\) Overall, the authors do not fully credit highly relevant studies in the literature. In addition to examples above, Blencowe\'s group published a particularly relevant study with remarkably similar findings to the present work last year that is not cited here (Quesnel-Vallieres et al., G & D 2015). They report that the loss of nSR100, an alternative splicing factor in neurons, gives rise to CC agenesis and to phrenic nerve defects. In addition, a mutation in nSR100 has been reported to cause hearing defects and should probably be cited along with the other two the authors cite in the statement \"to date only two alternative splicing factors have been implicated in hearing: *Srrm4* (Nakano et al. 2012) and *Sfswap* (Moayedi et al. 2014)\".

3\) Given the limitations of the Study, perhaps a more accurate title would be \"NOVA-2 mediated alternative splicing is required for axon pathfinding during development.\" Indeed, the data certainly demonstrate that this is the case. While \"regulatory networks\" allude to profound insights, to what extend this is true remains unclear, while it is clear that \"alternative splicing\" is important.

4\) The authors should provide schematic representations for the developmental systems to make the data more broadly accessible to readers. It would also be helpful to make it clear to the reader that the specific phenotypes are complex and as NOVA-2 is broadly expressed how specific developmental defects arise may be a consequence not only of changes in transcripts in a specific cell type, but also changes in transcripts in different ways in different neurons. That is, the phenotypic analysis assumes cell autonomy and no data addresses this issue in the paper.

5\) Furthermore, whether these axon guidance defects arise solely from alteration of transcripts involved in axon guidance or indirectly by disrupting the regulation of other genes involved in neuronal differentiation is unclear. That said, at least some guidance receptors are targets for NOVA-2 regulation and this observation as well as observations in the companion paper provide support for a direct role in this process. It is important to note, however, that the GO analysis presented in the supplementary material [Figure 3---source data 1](#SD1-data){ref-type="supplementary-material"} indicates that other categories of genes are also significantly altered in NOVA-2 mutants, including genes involved protein modification, phosphorlyation, metabolism and chromatin modification. Thus, to what extent the observed phenotypes reflect alterations in axon guidance receptors per se, as opposed to proteins acting to regulate neuronal differentiation more generally and axon guidance only indirectly remains unclear. All this needs to be addressed in the Discussion.

6\) The significance of the changes in axon guidance receptors is discussed in the context of the long and short forms of DCC, the netrin receptor. This discussion really belongs in the other manuscript by Chen et al., and that focuses specifically on the NOVA-2 regulation of this pathway.

*Reviewer \#1:*

The manuscript investigates the functional differences between the two Nova isoforms, Nova1 and Nova2. The authors compare transcriptome-wide HITS-CLIP and RNA-seq data from *Nova1* and *Nova2* mutants and report evidence showing that Nova2 uniquely regulates the alternative splicing of axon guidance-related genes in cortical development. They also report that loss of Nova2, but not Nova1, gives rise to axonal defects in the cortex, spinal cord and brainstem, particularly in ventral motoneuron axons. Overall, the results indicate that Nova2 controls alternative splicing of some key components involved in axon guidance.

This is an interesting study that compares Nova1 and Nova2 target transcripts and function. The study follows up on previous work from Darnell and colleagues and provides novel evidence for distinct isoform-specific targets and function. The transcriptome-wide analyses are robust and compelling. The functional axonal defects seen with loss of Nova2A are very clear and well described. However, the study does not identify the Nova2A targets that underlie the axon guidance defects. This weakness could potentially be addressed by further experiments.

1\) The loss of the corpus callosum is a severe and convincing phenotype in *Nova2* mutants. The authors focus their discussion of this phenotype almost entirely on the netrin-1/DCC signaling pathway for the good reason that Nova2 regulates the alternative splicing of two netrin receptors, DCC and Neo1. However, they do not test this directly. The link between the splicing target and the phenotype would be significantly strengthened by the addition of data testing whether DCC or Neo1 can rescue the ACC phenotype. These would be challenging but valuable experiments.

Without the DCC or Neo1 rescue experiments, the authors should widen the discussion about the possible targets affected in the Nova2A mutant that could give rise to the agenesis phenotype. There are around 60 mouse genes known to be required for the formation of the corpus callosum (e.g. Paul et al. 2007; Donahoo and Richards, 2012) so it would valuable to try to establish how many of these identified genes are targets of Nova2. How many of these 60 genes are present in the Nova2A target data? Loss of Neuropilin1, for example, gives rise to ACC (Lim et al. 2015) and the EphB1 and EphB2 intracellular signalling domains are required for the formation of the CC (Robichaux et al. 2015). These two studies also report the loss of the anterior commissure in addition to the CC. Does the *Nova2* mutant show a defect in axons crossing the AC?

2\) Overall, the authors do not fully credit highly relevant studies in the literature. In addition to examples above, Blencowe\'s group published a particularly relevant study with remarkably similar findings to the present work last year that is not cited here (Quesnel-Vallieres et al., G & D 2015). They report that the loss of nSR100, an alternative splicing factor in neurons, gives rise to CC agenesis and to phrenic nerve defects. In addition, a mutation in nSR100 has been reported to cause hearing defects and should probably be cited along with the other two the authors cite in the statement \"to date only two alternative splicing factors have been implicated in hearing: *Srrm4* (Nakano et al. 2012) and *Sfswap* (Moayedi et al. 2014)\".

*Reviewer \#2:*

This is a provocative paper from Darnell and colleagues. Using a combination of HITS-CLIP and RNA-sequencing, transcripts encoding proteins regulating axon guidance were identified as targets preferentially regulated by the NOVA-2 splicing factor (selectively when compared to NOVA-1). Additional data are presented in support of specific alternative splicing events selectively regulating axon guidance receptors via a NOVA-2 dependent mechanism. In the second part of the paper, genetic studies are presented demonstrating defects in axon guidance in different developmental contexts. The authors argue that these data support the conclusion as stated in their title \"NOVA-1 mediated RNA regulatory networks are required for axonal pathfinding during development\". Perhaps a more accurate title would be \"NOVA-2 mediated alternative splicing is required for axon pathfinding during development.\" Indeed, the data certainly demonstrate that this is the case. While \"regulatory networks\" allude to profound insights, to what extend this is true remains unclear, while it is clear that \"alternative splicing\" is important.

The RNA-sequencing and HITS clip data are impressive and comprehensive and reveal an impressive array of transcripts selectively regulated by NOVA-2. Together this makes a compelling argument that NOVA-2 broadly sculpts the neuronal proteome. The genetic data establish marked axon guidance defects in several different developmental contexts and thus broadly supports the notion of a critical role for NOVA-2 in regulating axon guidance. These data are compelling. My only suggestion here is that the authors provide schematic representations for the developmental systems to make the data more broadly accessible to readers. It would also be helpful to make it clear to the reader that the specific phenotypes are complex and as NOVA-2 is broadly expressed how specific developmental defects arise may be a consequence not only of changes in transcripts in a specific cell type, but also changes in transcripts in different ways in different neurons. That is, the phenotypic analysis assumes cell autonomy and no data addresses this issue in the paper.

Furthermore, whether these axon guidance defects arise solely from alteration of transcripts involved in axon guidance or indirectly by disrupting the regulating of other genes involved in neuronal differentiation is unclear. That said, at least some guidance receptors are targets for NOVA-2 regulation and this observation as well as observations in the companion paper provide support for a direct role in this process. It is important to note, however, that the GO analysis presented in the supplementary material [Figure 3---source data 1](#SD1-data){ref-type="supplementary-material"} indicates that other categories of genes are also significantly altered in NOVA-2 mutants, including genes involved protein modification, phosphorlyation, metabolism and chromatin modification. Thus, to what extent the observed phenotypes reflect alterations in axon guidance receptors per se, as opposed to proteins acting to regulate neuronal differentiation more generally and axon guidance only indirectly remains unclear.

The significance of the changes in axon guidance receptors is discussed in the context of the long and short forms of DCC, the netrin receptor. This discussion really belongs in the other manuscript that focuses specifically on the NOVA-2 regulation of this pathway.

In general, I feel that the two papers together certainly are greater than the sum of the two. I suggest that authors play down the notion of a network here as it says very little and implies a level of understanding that is by no means achieved here. Perhaps, the authors could move the discussion of DCC from this manuscript to the other one, and use the space to address the question of how NOVA-2 regulates neural development, and perhaps expand this to explore the relationship to other global splicing regulators of neuronal differentiation such RbFox.

*Reviewer \#3:*

This work provides an extensive analysis of loss-of-function phenotypes for NOVA1 and NOVA2 mutant mice. Using a combination of genome-wide approaches the authors identify an alternative splicing program regulated by the NOVA RNA-binding proteins. This analysis extends previously reported data sets on such targets.

Amongst many other targets, there is a significant de-regulation of several axon guidance regulators, in particular components that have been shown to contribute to growth and guidance at the midline. In parallel, the authors report a series of axon extension and guidance phenotypes in the mutant mice.

The datasets are extensive and rigorous. What is a weakness of the work is the lack of data demonstrating a causal link between any of the splicing targets and the anatomical phenotypes.

There is also no insight into how the alternative splice isoforms of the guidance receptors may differ in activity.

The main contributions of the work are the description of novel anatomical phenotypes and splicing targets, as well as the identification of distinct phenotypes in NOVA2 versus NOVA1 mutant mice. However, the mechanism underlying this apparent specificity remains unclear (cell type-specificity of NOVA isoform expression or unique interactions with co-factors or RNA elements?).

The data is clear, analysis rigorous, and the interpretation of the results is appropriate. Adding more mechanism would mean a substantial amount of experimental work. In the present form this appears to me like a borderline case for publication in *eLife*.

10.7554/eLife.14371.035

Author response

The issues that must be addressed:

1\) The loss of the corpus callosum is a severe and convincing phenotype in Nova2 mutants. The authors focus their discussion of this phenotype almost entirely on the netrin-1/DCC signaling pathway for the good reason that Nova2 regulates the alternative splicing of two netrin receptors, DCC and Neo1. However, they do not test this directly. The link between the splicing target and the phenotype would be significantly strengthened by the addition of data testing whether DCC or Neo1 can rescue the ACC phenotype. These would be challenging but valuable experiments.

We appreciate the reviewers' suggestion, and have tried this challenging experiment. Since it has not been reported that *Neo1* KO mice have ACC phenotype, we tried to rescue the ACC phenotype with the DCC-‐long isoform that is decreased in the cortex of *Nova2*-‐KO mice. We undertook in uteroelectroporation of plasmids expressing the DCC-‐long isoform. Plasmid expressing both the *DCC* long isoform and DsRed as a positive control were electroporated into the cingulate cortex at E14.5, the mice were sacrificed at E17.5, and subjected to immunostaining with L1 and DsRed ([Author response image 1](#fig12){ref-type="fig"}). The expression of DCC-‐long isoform in cingulate cortex at E14.5 was not sufficient to form the commissure corpus callosum, indicating that the DCC-‐long isoform was not sufficient to rescue the ACC phenotype, and suggesting the possibility that the ACC phenotype in *Nova2-*KO mice either does not involve the DCC-‐long isoform or is caused by the dysregulation of multiple transcriptomes. We mention this negative result in the revised Discussion part.10.7554/eLife.14371.031Author Response Image 1.**DOI:** [http://dx.doi.org/10.7554/eLife.14371.031](10.7554/eLife.14371.031)

Without the DCC or Neo1 rescue experiments, the authors should widen the discussion about the possible targets affected in the Nova2A mutant that could give rise to the agenesis phenotype. There are around 60 mouse genes known to be required for the formation of the corpus callosum (e.g. Paul et al. 2007; Donahoo and Richards, 2012) so it would valuable to try to establish how many of these identified genes are targets of Nova2. How many of these 60 genes are present in the Nova2A target data? Loss of Neuropilin1, for example, gives rise to ACC (Lim et al. 2015) and the EphB1 and EphB2 intracellular signalling domains are required for the formation of the CC (Robichaux et al. 2015).

We appreciate the reviewers' point, and have widened the discussion about possible targets affected in the *Nova2*-KO that could give rise to the ACC phenotype, based on great review articles (Paul et al., 2007; Edwards, et al., 2014) and the genes that reviewers suggested (*Neuropilin1, EphB1, EphB2, nSR100/Srrm4*). This suggestion prompted us to find 6 additional *Nova2* dependent alternative splicing events on 5 genes that associated with human ACC syndromes and mouse ACC phenotypes (*Ank2, Dclk1, Enah, Cask, Ptprs*;). This has now been added to the revised manuscript ([Figure 6---figure supplement 3](#fig6s3){ref-type="fig"}).

These two studies also report the loss of the anterior commissure in addition to the CC. Does the Nova2 mutant show a defect in axons crossing the AC?

A defect in axons crossing the anterior commissure midline was not observed in *Nova2*-KO mice (5/5 mice) (red arrowin [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}: DAPI stain at E18.5). This point and data has now been added to the text ([Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}).

2\) Overall, the authors do not fully credit highly relevant studies in the literature. In addition to examples above, Blencowe\'s group published a particularly relevant study with remarkably similar findings to the present work last year that is not cited here (Quesnel-Vallieres et al., G & D 2015). They report that the loss of nSR100, an alternative splicing factor in neurons, gives rise to CC agenesis and to phrenic nerve defects. In addition, a mutation in nSR100 has been reported to cause hearing defects and should probably be cited along with the other two the authors cite in the statement \"to date only two alternative splicing factors have been implicated in hearing: Srrm4 (Nakano et al. 2012) and Sfswap (Moayedi et al. 2014)\".

We now use *Srrm4/nSR100* to avoid confusion since *Srrm4* and *nSR100* are same gene. The article of *Srrm4/nSR100* exon 7-‐8 deletion mice (Quesnel-‐Vallieres M., et al., (2015) Genes Dev., 29(7):746-‐759) was cited as a relevant study with similar findings in CC and phrenic nerve to our present work; this is now clarified in the revised text. The statement about alternative splicing and hearing was likewise modified to "to date only two alternative splicing factors have been implicated in hearing: *Srrm4/nSR100* (Nakano et al. 2012) and *Sfswap* (Moayedi et al. 2014)".

3\) Given the limitations of the Study, perhaps a more accurate title would be \"NOVA-2 mediated alternative splicing is required for axon pathfinding during development.\" Indeed, the data certainly demonstrate that this is the case. While \"regulatory networks\" allude to profound insights, to what extend this is true remains unclear, while it is clear that \"alternative splicing\" is important.

We agree, and have changed the title to "NOVA2-‐mediated RNA regulation is required for axonal pathfinding during development" since although we focused on alternative splicing but NOVA2 also has other actions, including regulation of alternative poly(A) usage (Licataloci et al., (2008) Nature 456:464--69).

4\) The authors should provide schematic representations for the developmental systems to make the data more broadly accessible to readers. It would also be helpful to make it clear to the reader that the specific phenotypes are complex and as NOVA-2 is broadly expressed how specific developmental defects arise may be a consequence not only of changes in transcripts in a specific cell type, but also changes in transcripts in different ways in different neurons. That is, the phenotypic analysis assumes cell autonomy and no data addresses this issue in the paper.

We modified the schematic [Figure 11](#fig11){ref-type="fig"} and [Figure 11](#fig11){ref-type="fig"} legend. Also, we widened the discussion about alternative mechanisms (e.g. GO enriched pathway (protein modification, phosphorylation, metabolism and chromatin modification) and differentiation).

Although we could not distinguish the possibility that *Nova2* deficits cause abnormally differentiated neurons as a primary defect and thereby result in axonal pathfinding defects, we do note that our RNAseq data showed that the transcriptome abundance of the neuronal differentiation markers were comparative between wild-‐type and *Nova2*-‐KO mice (see [Figure 3---source data 2](#SD2-data){ref-type="supplementary-material"}). Our previous work (Yano M et al., (2010) Neuron66:848-‐858) has showed that the proliferation of neural progenitor cell (NPC) is not disrupted in *Nova2*-KO, suggesting that the differentiation from NPC to neuron is comparative between wild-‐type and *Nova2*-KO mice at least in the cortex. This point and data has now been added to the text ([Figure 3---source data 2](#SD2-data){ref-type="supplementary-material"}).

5\) Furthermore, whether these axon guidance defects arise solely from alteration of transcripts involved in axon guidance or indirectly by disrupting the regulation of other genes involved in neuronal differentiation is unclear. That said, at least some guidance receptors are targets for NOVA-2 regulation and this observation as well as observations in the companion paper provide support for a direct role in this process. It is important to note, however, that the GO analysis presented in the supplementary material [Figure 3---source data 1](#SD1-data){ref-type="supplementary-material"} indicates that other categories of genes are also significantly altered in NOVA-2 mutants, including genes involved protein modification, phosphorlyation, metabolism and chromatin modification. Thus, to what extent the observed phenotypes reflect alterations in axon guidance receptors per se, as opposed to proteins acting to regulate neuronal differentiation more generally and axon guidance only indirectly remains unclear. All this needs to be addressed in the Discussion.

As written in point 4, we widened the Discussion part about these concerns.

6\) The significance of the changes in axon guidance receptors is discussed in the context of the long and short forms of DCC, the netrin receptor. This discussion really belongs in the other manuscript by Chen et al., and that focuses specifically on the NOVA-2 regulation of this pathway.

We cross-‐cited our manuscripts with an accompanying paper by Leggere et al. and partially transfer our Discussion part to an accompanying paper by Leggere et al.

Reviewer \#1:

The manuscript investigates the functional differences between the two Nova isoforms, Nova1 and Nova2. The authors compare transcriptome-wide HITS-CLIP and RNA-seq data from Nova1 and Nova2 mutants and report evidence showing that Nova2 uniquely regulates the alternative splicing of axon guidance-related genes in cortical development. They also report that loss of Nova2, but not Nova1, gives rise to axonal defects in the cortex, spinal cord and brainstem, particularly in ventral motoneuron axons. Overall, the results indicate that Nova2 controls alternative splicing of some key components involved in axon guidance.

This is an interesting study that compares Nova1 and Nova2 target transcripts and function. The study follows up on previous work from Darnell and colleagues and provides novel evidence for distinct isoform-specific targets and function. The transcriptome-wide analyses are robust and compelling. The functional axonal defects seen with loss of Nova2A are very clear and well described. However, the study does not identify the Nova2A targets that underlie the axon guidance defects. This weakness could potentially be addressed by further experiments.

1\) The loss of the corpus callosum is a severe and convincing phenotype in Nova2 mutants. The authors focus their discussion of this phenotype almost entirely on the netrin-1/DCC signaling pathway for the good reason that Nova2 regulates the alternative splicing of two netrin receptors, DCC and Neo1. However, they do not test this directly. The link between the splicing target and the phenotype would be significantly strengthened by the addition of data testing whether DCC or Neo1 can rescue the ACC phenotype. These would be challenging but valuable experiments.

Without the DCC or Neo1 rescue experiments, the authors should widen the discussion about the possible targets affected in the Nova2A mutant that could give rise to the agenesis phenotype. There are around 60 mouse genes known to be required for the formation of the corpus callosum (e.g. Paul et al. 2007; Donahoo and Richards, 2012) so it would valuable to try to establish how many of these identified genes are targets of Nova2. How many of these 60 genes are present in the Nova2A target data? Loss of Neuropilin1, for example, gives rise to ACC (Lim et al. 2015) and the EphB1 and EphB2 intracellular signalling domains are required for the formation of the CC (Robichaux et al. 2015). These two studies also report the loss of the anterior commissure in addition to the CC. Does the Nova2 mutant show a defect in axons crossing the AC?

See answers to point 1 above.

2\) Overall, the authors do not fully credit highly relevant studies in the literature. In addition to examples above, Blencowe\'s group published a particularly relevant study with remarkably similar findings to the present work last year that is not cited here (Quesnel-Vallieres et al., G & D 2015). They report that the loss of nSR100, an alternative splicing factor in neurons, gives rise to CC agenesis and to phrenic nerve defects. In addition, a mutation in nSR100 has been reported to cause hearing defects and should probably be cited along with the other two the authors cite in the statement \"to date only two alternative splicing factors have been implicated in hearing: Srrm4 (Nakano et al. 2012) and Sfswap (Moayedi et al. 2014)\".

See answer to point 2 above.

Reviewer \#2:

This is a provocative paper from Darnell and colleagues. Using a combination of HITS-CLIP and RNA-sequencing, transcripts encoding proteins regulating axon guidance were identified as targets preferentially regulated by the NOVA-2 splicing factor (selectively when compared to NOVA-1). Additional data are presented in support of specific alternative splicing events selectively regulating axon guidance receptors via a NOVA-2 dependent mechanism. In the second part of the paper, genetic studies are presented demonstrating defects in axon guidance in different developmental contexts. The authors argue that these data support the conclusion as stated in their title \"NOVA-1 mediated RNA regulatory networks are required for axonal pathfinding during development\". Perhaps a more accurate title would be \"NOVA-2 mediated alternative splicing is required for axon pathfinding during development.\" Indeed, the data certainly demonstrate that this is the case. While \"regulatory networks\" allude to profound insights, to what extend this is true remains unclear, while it is clear that \"alternative splicing\" is important.

See answer to point 3 above.

The RNA-sequencing and HITS clip data are impressive and comprehensive and reveal an impressive array of transcripts selectively regulated by NOVA-2. Together this makes a compelling argument that NOVA-2 broadly sculpts the neuronal proteome. The genetic data establish marked axon guidance defects in several different developmental contexts and thus broadly supports the notion of a critical role for NOVA-2 in regulating axon guidance. These data are compelling. My only suggestion here is that the authors provide schematic representations for the developmental systems to make the data more broadly accessible to readers. It would also be helpful to make it clear to the reader that the specific phenotypes are complex and as NOVA-2 is broadly expressed how specific developmental defects arise may be a consequence not only of changes in transcripts in a specific cell type, but also changes in transcripts in different ways in different neurons. That is, the phenotypic analysis assumes cell autonomy and no data addresses this issue in the paper.

See answer to point 4 above.

Furthermore, whether these axon guidance defects arise solely from alteration of transcripts involved in axon guidance or indirectly by disrupting the regulating of other genes involved in neuronal differentiation is unclear. That said, at least some guidance receptors are targets for NOVA-2 regulation and this observation as well as observations in the companion paper provide support for a direct role in this process. It is important to note, however, that the GO analysis presented in the supplementary material [Figure 3---source data 1](#SD1-data){ref-type="supplementary-material"} indicates that other categories of genes are also significantly altered in NOVA-2 mutants, including genes involved protein modification, phosphorlyation, metabolism and chromatin modification. Thus, to what extent the observed phenotypes reflect alterations in axon guidance receptors per se, as opposed to proteins acting to regulate neuronal differentiation more generally and axon guidance only indirectly remains unclear.

See answer to point 5 above.

The significance of the changes in axon guidance receptors is discussed in the context of the long and short forms of DCC, the netrin receptor. This discussion really belongs in the other manuscript that focuses specifically on the NOVA-2 regulation of this pathway.

See answer to point 6 above.

In general, I feel that the two papers together certainly are greater than the sum of the two. I suggest that authors play down the notion of a network here as it says very little and implies a level of understanding that is by no means achieved here. Perhaps, the authors could move the discussion of DCC from this manuscript to the other one, and use the space to address the question of how NOVA-2 regulates neural development, and perhaps expand this to explore the relationship to other global splicing regulators of neuronal differentiation such RbFox.

We cross-‐cited our manuscripts with an accompanying paper by Leggere et al. and expanded our Discussion to clarify the contributions of Leggere et al.

Reviewer \#3:

This work provides an extensive analysis of loss-of-function phenotypes for NOVA1 and NOVA2 mutant mice. Using a combination of genome-wide approaches the authors identify an alternative splicing program regulated by the NOVA RNA-binding proteins. This analysis extends previously reported data sets on such targets.

Amongst many other targets, there is a significant de-regulation of several axon guidance regulators, in particular components that have been shown to contribute to growth and guidance at the midline. In parallel, the authors report a series of axon extension and guidance phenotypes in the mutant mice.

The datasets are extensive and rigorous. What is a weakness of the work is the lack of data demonstrating a causal link between any of the splicing targets and the anatomical phenotypes.

There is also no insight into how the alternative splice isoforms of the guidance receptors may differ in activity.

The main contributions of the work are the description of novel anatomical phenotypes and splicing targets, as well as the identification of distinct phenotypes in NOVA2 versus NOVA1 mutant mice. However, the mechanism underlying this apparent specificity remains unclear (cell type-specificity of NOVA isoform expression or unique interactions with co-factors or RNA elements?).

Since RNA binding KH domains of both NOVA1 and NOVA2 are identical, the differences in function between NOVA1 and NOVA2 may be derived from the expression, cell milieu, and/or protein-‐protein interaction. As mentioned in the Discussion part largest difference is in spacer domain between KH2 and KH3, although there is no known function of this region. We also widen the Discussion about this point.

[^1]: Department of Neurosciences, Faculty of Medicine, University of Montreal, Montreal, Canada.
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